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Pancreatic tumor is one of the leading causes of cancer-related deaths in the world. 
Currently, the nucleoside analogue gemcitabine is the leading therapeutic drug for the 
treatment of pancreatic tumors. However, due to an ever-increasing number of patients 
developing gemcitabine resistance, there is a renewed interest in developing more 
efficient treatment regimes.  
Combination therapy that utilizes gemcitabine with other chemotherapeutic drugs or 
biological agents has the potential to overcome issues with traditional gemcitabine 
therapy. Gemcitabine acts by inducing replicative stress and consequently, cell cycle 
checkpoint kinases are activated. Tumor cells have more efficient checkpoint control, 
which could ultimately cause resistance towards gemcitabine. Therefore, inhibitors 
against checkpoint kinases are attractive candidates for tumor treatment in combination 
with gemcitabine. In this study, we have evaluated the sensitization of several pancreatic 
tumor cell lines (Panc1, MiaPaCa2 and BxPC3) towards gemcitabine upon inhibition of 
Chk1, Wee1 and ATR checkpoint kinases. We find that inhibition of these checkpoint 
kinases with specific chemical inhibitors sensitize pancreatic tumor cells against 
gemcitabine. Of these, the combination of Wee1 inhibitor, MK-1775 with gemcitabine 
shows high efficiency in decreasing the long-term survivability of cells and elimination of 
pancreatic tumor cells.  
Through western blot analysis, we find that Wee1 inhibition along with gemcitabine 
treatment causes inactivation of the ATR signaling pathway. We show that apoptosis and 
mitotic catastrophe do not cause the reduction in ATR-Chk1 activity. Interestingly, the 
attenuation of ATR-Chk1 pathway can be rescued by simultaneous inhibition of Cdks. 
Surprisingly, we find that simultaneous inhibition of Plk1 along with Wee1 inhibition and 
gemcitabine treatment can also recover the decreased ATR-Chk1 activity. We observe 
that activation of Plk1 upon Wee1 inhibition along with gemcitabine is dependent on Cdks. 
Moreover, we also show that Plk1 mediates inactivation of Chk1 through Claspin 
degradation.  
In order to reduce the toxic effects of the combined treatment of Wee1 inhibitor with 
gemcitabine in normal proliferating cells with wild-type p53, we tested Mdm2 antagonist, 
nutlin-3 pretreatment. We find that indeed nutlin-3 pretreatment can decrease the DNA 




by Wee1 inhibition with gemcitabine. As expected, this virtue of nutlin-3 pretreatment is 
dependent on p53 status of the cells.  
In conclusion, our study shows that the efficiency of Wee1 inhibition and gemcitabine 
treatment is not solely dependent on cell cycle dysregulation but also on the replicative 
stress.  Since most of the pancreatic tumors have mutated form of p53, we propose that 
pretreatment with Mdm2 antagonists at sub-lethal dose can provide protection to fast 
proliferating cells with wild-type p53 against toxic effects of combination of Wee1 inhibition 






II.1 Chemotherapeutic drugs 
Cancer is a group of diseases which involve abnormal division of cells and their spreading 
to other parts of the body. Cancer management involves several procedures including 
surgery, radiotherapy and chemotherapy. Chemotherapy uses one or more cytotoxic anti-
neoplastic drugs (McKnight 2003). Chemotherapeutic drugs have been classically 
categorized based on their chemical structure and mechanism of action: Alkylating 
agents, antibiotics, antimetabolites, topoisomerase I and II inhibitors, mitosis inhibitors, 
platinum compounds and others (Espinosa et al. 2003). Among these categories of the 
drugs, antimetabolites comprise the structural analogs of naturally occurring metabolites 
involved in RNA or DNA synthesis (Malhotra and Perry 2003).  
 
II.2 Nucleoside analogs 
Nucleoside analogs are the antimetabolites which are structurally similar to nucleosides, 
have a broad range of action, and are clinically active in both solid tumors and 
hematological malignancies (B Ewald, Sampath, and Plunkett 2008).  
II.2.1.1 Classification 
Nucleoside analogs can be sub-categorized into pyrimidine analogs and purine analogs. 
Pyrimidine analogs are deoxycytidine derivatives and include gemcitabine, ara-C (or 
cytarabine), troxacitabine. They get incorporated into the replicating DNA and this is at 
least one of the major mechanisms of their cytotoxicity, ribonucleotide reductase inhibition 
is also important in the case of gemcitabine. Likewise, purine analogs are derivatives of 
deoxyadenosine such as fludarabine, cladrabine, clofarabine. Purine analogs exert their 
cytotoxic effects by getting incorporated into both DNA and RNA. Furthermore, they can 
activate DNA-independent processes to promote apoptosis (they change the 
mitochondrial membrane potential leading to release of cytochrome c; which, in turn, 
binds to other pro-apoptotic proteins to form an active apoptotic complex called the 
apoptosome). Purine analogs have been found to be potent in B-cell malignancies while 
pyrimidine analogs are active in a broad spectrum of solid tumors (Daskalakis et al. 2002, 




II.2.1.2 Mechanism of action 
The triphosphates of nucleoside analogs compete with natural nucleotides for 
incorporation into the DNA by DNA polymerases causing steric hindrance to the 
extending replication forks, thereby leading to fork stalling (Kufe et al. 1980, Huang et al. 
1991). As these agents exert their cytotoxic effects after getting incorporated into the 
DNA, they are predominantly active in cells undergoing active DNA replication or excision 
repair synthesis (Huang, Chubb, and Plunkett 1990, Yamauchi et al. 2001). Once 
replication is blocked, cells activate the intra S-phase checkpoint which halts DNA 
replication and causes S-phase arrest discussed further in section II.3.2 (Shi et al. 2001, 
Sampath, Shi, and Plunkett 2002, Y.-W. Zhang, Hunter, and Abraham 2006). However, 
these evolutionary conserved mechanisms of safeguarding the genome are exploited by 
nucleoside analogs and other DNA-targeting drugs to cause enhanced cell killing. They 
effectuate cell death either by direct activation of the apoptosome (Genini et al. 2000, 
Bellosillo et al. 2002, Riedl and Salvesen 2007) or through epigenetic modifications 
(Stresemann and Lyko 2008). 
. 
II.3 The cell cycle and its regulation upon DNA damage 
II.3.1 Controllers of the cell cycle  
Cyclin dependent protein kinases (cdks) are among the major regulators of the cell cycle. 
Cdks are the catalytic subunits that dimerize with regulatory subunits, cyclins, to get 
activated. In humans, 11 genes have been shown to encode different Cdks that associate 
with specific cyclins in a cell cycle dependent manner (Malumbres et al. 2009), and are 
subsequently phosphorylated by a Cdk-activating kinases (CAKs) to form active 
complexes (Morgan 1995). 
Transition from G0-G1 (in quiescent cells) and early G1 (in proliferating cells) has been 
found to involve Cdk4–CyclinD, Cdk6–CyclinD and Cdk3–CyclinC complexes (at least in 
human cells), which mediate their action by phosphorylating the retinoblastoma protein 
(pRb). Cdk2–CyclinE complex has been proposed to complete the phosphorylation of 
pRb, therefore, allowing the cells to proceed through the cell cycle. Cdk2–CyclinE 
complex has also been implicated in the G1–S transition by licensing DNA origins of 
replication. Cdk2 later associates with CyclinA during progression through the S phase. 
Cdk1 participates in the S–G2 and G2–M transitions by sequential binding to Cyclin A and 




pRb is a tumor suppressor protein that regulates G1-S transition of the cell cycle and 
differentiation depending on the type of cellular proteins it binds (Taya 1997). Two well- 
known substrates of pRb are E2F and Histone deacetylases (HDACs). pRb interacts with 
E2F and HDACs forming a trimeric complex that represses transcription of a number of 
cell cycle regulated proteins (Harbour and Dean 2000). 
 
Figure II-I Oscillation of cyclin-cdk complexes in the cell cycle.  
Different combinations of cyclin-cdk complexes play role in driving the cell through various phases 
of the cell cycle.  
 
II.3.2 DNA damage response pathways 
In general, DNA damage or obstruction of DNA replication results in the recruitment of an 
array of molecular factors that comprise the DNA damage response machinery. These 
molecular factors bring about the cellular response to the DNA damage either by 
activating checkpoints, initiating DNA repair or causing cell death. When DNA damage 
either through UV or replicative stress is encountered by the cells, they respond to it by 
activating a series of proteins that co-ordinates DNA replication, DNA repair and cell-cycle 
progression and regulates processes such as firing of replication origins (Santocanale 
and Diffley 1998, Shirahige et al. 1998, Santocanale, Sharma, and Diffley 1999), 
stabilization of DNA replication forks in response to DNA damage or replicative stress 
(Lopes et al. 2001, Tercero and Diffley 2001), resumption of stalled DNA replication forks 




response genes (Allen et al. 1994), choice of the repair pathway (Kai et al. 2007) and 
inhibition of mitosis until replication is completed (Allen et al. 1994). Central among these 
are three phosphoinositide 3-kinase-related protein kinases (PIKKs) or serine/threonine 
kinases- Ataxia-telangiectasia mutated (ATM), Ataxia-telangiectasia mutated and rad3-
related (ATR) and DNA-dependent protein kinase (DNA-PK) (B Ewald, Sampath, and 
Plunkett 2008). 
II.3.2.1 ATR-Chk1 pathway 
Stalling of replication forks results in single-stranded DNA (ssDNA) that gets coated by 
replication protein A (RPA), which then recruits ATR. ATR is specific for ssDNA and 
interacts with ATR interacting protein (ATRIP) which serves as a platform for ATR 
activation (Cortez et al. 2001). Once ATR is recruited to DNA damage site, it gets auto-
phosphorylated at Thr1989, which is important for its activation (S. Liu et al. 2011). Upon 
failing to stabilize forks, ATR can activate the apoptotic machinery directly or through 
Chk1 that phosphorylates and thus, activates p53 (Tibbetts et al. 1999, Shieh et al. 2000). 
Like ATR, Rad17 is also recruited to the sites of RPA coated single- stranded DNA but 
independently of ATR (Zou and Elledge 2003, Melo, Cohen, and Toczyski 2001). Rad17, 
along with the four small subunits of replication factor C (RFC2-5), acts as a clamp loader 
of Rad9-Rad1-Hus1 (9-1-1) at or near the sites of DNA damage (Zou, Cortez, and Elledge 
2002). 9-1-1, in turn, recruits DNA topoisomerase2-binding protein1 (TopBP1) that 
recognizes auto-phosphorylated site on ATR (Thr1989) and thus, activates it (Delacroix et 
al. 2007, Akiko Kumagai et al. 2006, J. Lee, Kumagai, and Dunphy 2007). Depicted in 
Figure II-II. 
ATR activates Chk1 by phosphorylating Claspin, thereby creating a docking site for Chk1 
and its subsequent phosphorylation by ATR at Ser317 and Ser345 (Akiko Kumagai and 
Dunphy 2003, (Q. Liu et al. 2000), Guo et al. 2000, (H Zhao and Piwnica-Worms 2001). 
After ATR-induced phosphorylation, Chk1 undergoes autophosphorylation at Ser296 
(Kasahara et al. 2010). Once phosphorylated, Chk1 dissociates from chromatin;  thus, 
ATR regulation of Chk1 may control the transmission of DNA damage signals from 
chromatin to its targets (Smits, Reaper, and Jackson 2006). Chk1 mediates cell cycle 
regulation by phosphorylating Cdc25 phosphatase and activating Wee1 that directly 
inhibit Cyclin-dependent kinases (Cdks) activity by phosphorylation at Tyr 15 (J. Lee, 
Kumagai, and Dunphy 2001, Rothblum-Oviatt, Ryan, and Piwnica-Worms 2001). It has 
also been shown that phosphorylation of Rad17 by ATR at Ser635 and Ser645 is required 






Figure II-II Activation of ATR-Chk1 pathway.  
Upon induction of single-strand DNA breaks, a plethora of proteins are recruited to the site of damage 
and initiates the activation of ATR. Activated ATR, then phosphorylates downstream effector kinase, 
Chk1 which mediates cell cycle arrest, DNA repair and/or apoptosis. Adapted from (Smits et al. 2010, 
S. Liu et al. 2011) 
 
II.3.2.2 ATM-Chk2 pathway 
Stalled replication forks can also give rise to DSB either due to replication fork collapse or 
during processing of the exposed single stranded DNA (Sorensen and Syljuasen 2012). 
ATR promotes replication fork stabilization at stalled replication forks by controlling 
replisome-fork association and DNA polymerase stabilization (Cobb et al. 2003, Lucca et 
al. 2004, (Lopes et al. 2001). If the stalled forks are not stabilized, or if they persist for 
extended periods of time, they collapse and result in DSB. The situation can be remedied 
by homologous recombination; further, endonucleases such as Mus81/Eme1 can resolve 
the transient DNA structures (Sogo, Lopes, and Foiani 2002, Zhou and Elledge 2000).  
Following DNA damage, nuclear ATM dimers dissociate into active monomers on 
autophosphorylation of Ser1981 and localize to sites of DNA damage (Bakkenist and 




2005) . As a central kinase in triggering cellular responses, ATM can phosphorylate 
several substrates including the variant histone, H2AX, to form the DNA damage-
associated histone marker, γH2AX (Fernandez-Capetillo et al. 2004). Additionally, it also 
phosphorylates the downstream effector kinase Chk2 at Thr68 (Lukas et al. 2003), NBS1 
of MRN complex (Bolderson et al. 2004), the cohesin SMC1 (Kitagawa et al. 2004), 
transcription factor p53 (Lavin and Kozlov 2007), the ‘master regulator’ of recognition and 
repair process MDC1, and other repair factors BRCA1 and p53BP1 (Lavin 2008). Once 
activated, Chk2 acts on multiple substrates involved in cell cycle progression (Cdc25 
(Blasina et al. 1999)); apoptosis (p53 (Nabil H. Chehab et al. 2000)) and gene 
transcription (transcription factors such as E2F1 (Stevens, Smith, and La Thangue 2003)). 
Refer to Figure II-III 
ATR is predominantly required for activation of DNA damage checkpoints in response to 
replication stress, while ATM is the primary mediator for the response to DSB (Yosef 
Shiloh 2003). Interestingly, evidence from two independent groups suggests activation of 
ATR by ATM in response to ionizing radiation (IR)-induced DSB (Jazayeri et al. 2006, 
Myers and Cortez 2006). Moreover, it has been shown that ATM becomes 
autophosphorylated on its activation site, Ser1981, co-localizes at the sites of replication 
forks induced by nucleoside analogs, and is required for survival upon induction of DSB in 
response to IR (Karnitz et al. 2005, Brett Ewald, Sampath, and Plunkett 2007). These 
findings throw light on the convergence of the two pathways in response to DNA damage. 
II.3.2.3 Phosphorylated H2AX (or γH2AX) 
H2AX belongs to the H2A family of histone proteins, one of the five families of histone that 
package and organize eukaryotic DNA into chromatin. Each nucleosome contains two 
H2A molecules, of which ~ 10% are H2AX in normal human fibroblasts; this translates 
into an H2AX molecule on every fifth nucleosome on average. However, the percentage 
of H2AX can vary from as low as 2% (in lymphocytes and Hela cells) to as high as 20% 
(in SF268, a human glioma cell line) (E P Rogakou et al. 1998). Phosphorylation of H2AX 
at Ser139 had initially been associated with DSB formation (Emmy P. Rogakou et al. 
1998). Apart from ATR and ATM, DNA-PK mediates phosphorylation of H2AX in cells 
under hypertonic conditions and during apoptotic DNA fragmentation (Reitsema et al. 
2005, Mukherjee et al. 2006). Initially, H2AX molecules in a small region near the DSB 
site are phosphorylated, which is followed by molecules at increasing distances from the 
break site that can include millions of base pairs (E P Rogakou et al. 1999). Many DNA 
repair and/or checkpoint proteins accumulate on the growing γH2AX focus, which may 
serve to open up the chromatin structure (Kruhlak et al. 2006, Niels Mailand et al. 2007) 




(Paull et al. 2000). Once the damaged DNA is repaired, γH2AX foci disappear, probably 
due to dephosphorylation by phosphatases PP2A and PP4C (Chowdhury et al. 2005, 
Chowdhury et al. 2008) or removal of γH2AX from chromatin by histone exchange 
(Downs et al. 2004) 
II.3.3 Cyclin-dependent kinases in the DNA damage response 
In response to DNA damage, Cdks activity is negatively regulated. Apart from regulation 
by Chk1 and Wee1, various other regulators are present which compete with cyclins in 
binding to specific Cdks, thereby inhibiting their activity. These regulators have been 
termed as Cdk inhibitors or CKIs and are classified into two families based on their 
specificity of interaction with Cdks and sequence homology. One of the families is INK4 
which consists of proteins having ankyrin-like repeats. Members of this family are p15 and 
p16 and they bind to Cdk4/6. Other family is Cip/Kip which includes p21 and p27 and they 
inhibit Cdk2 (M. H. Lee and Yang 2001). Cdk2 has been proposed to activate Mus81- 
Eme1 endonuclease by its phosphorylation. Moreover, upon depletion of Wee1, hyper-
activated Cdk2 can cause increase in Mus81 activity which then triggers DNA damage 
response (Dominguez-Kelly et al. 2011). 
II.3.4 Checkpoint kinases in cell cycle regulation following DNA damage 
Three checkpoints operate during the cell cycle, namely G1-, intra S- and G2/M- phase 
checkpoints. These checkpoints get activated in response to DNA damage and function to 
halt the cell cycle progression and signal downstream to repair factors to maintain the 
integrity of genome as summarized in Figure II-III. 
II.3.4.1 The G1 checkpoint 
Regulation of G1 checkpoint has been proposed by a two-wave model wherein a p53 
independent, rapid and transient initial response is followed by a delayed, yet sustained, 
p53-dependent response (Bartek and Lukas 2001). Early response after exposure to IR or 
UV is mediated by Cdc25A phosphatase degradation, initiated by ATM/ATR pathway 
activation in response to DNA damage. UV and IR elicit the phosphorylation of Cdc25A at 
several amino-terminal serine residues by Chk1, downstream of ATR (N Mailand et al. 
2000) and Chk2, activated by ATM (Falck et al. 2001). Phosphorylation of Cdc25A 
triggers its proteasomal degradation; as a consequence Cdc25A is no longer available to 
promote the activity of cyclin E (A)/cdk2 by removing the inhibitory phosphates at Thr14 
and Tyr15 on Cdk2 (Tse, Carvajal, and Schwartz 2007). The outcome of this cascade is 
inhibition of Cdk2-dependent loading of Cdc45, an initiator of DNA replication, onto DNA 




A delayed response to sustain G1 arrest has been ascribed to p53, a tumor suppressor 
protein that functions as a transcription factor. Upon induction of stress stimuli, p53 is 
post-transcriptionally modified and stabilized; moreover, its sequence-specific DNA 
binding is activated (Bert Vogelstein, Lane, and Levine 2000). Once activated, p53 can 
stimulate the transcription of its target genes; one of them is p21, which inhibits Cdks and 
therefore, blocks cell cycle progression. However, for the activation of p53, ATM/ATR and 
Chk2/Chk1 are required, wherein ATM (and also likely ATR) phosphorylates Mdm2 (at 
Ser395) which deregulates the nuclear transport of p53. It also phosphorylates and 
activates p53 at Ser15 and some other residues. (Maya et al. 2001, Y. Zhang and Xiong 
2001, Kastan and Lim 2000, Y Shiloh 2001, Ryan, Phillips, and Vousden 2001).  
Phosphorylation of p53 by Chk2/Chk1 at Ser20 helps stabilize p53 by uncoupling it from 
Mdm2 Ubiquitin ligase (N H Chehab et al. 2000, Hirao et al. 2000, S. Y. Shieh et al. 
2000). Thus, two waves of G1 checkpoint are activated simultaneously but their effect on 
Cdk activity and consequently on G1 blockage varies in time, due to dependence of p53 
pathway on transcription and protein synthesis (Bartek and Lukas 2001). 
II.3.4.2 The intra-S checkpoint 
The ATR and ATM pathways that operate during G1 are also active during S-phase.In 
parallel to activation of Chk2, ATM also phosphorylates SMC1 with the aid of BRCA1, 
FANCD2 and NBS1 that play an active role in repair of DSB or recovery of collapsed 
replication forks (S.-T. Kim, Xu, and Kastan 2002, Yazdi et al. 2002).  
II.3.4.3 The G2/M checkpoint 
The G2/M checkpoint prevents cells from undergoing mitosis in the presence of DNA 
damage. This checkpoint also employs the ATR-Chk1 or ATM-Chk2 pathways, depending 
on the type of damage. In both cases, checkpoint kinases inhibit entry into mitosis by 
down-regulating Cdc25 and up-regulating Wee1, which together control Cdc2/CyclinB 
activity (Furnari, Rhind, and Russell 1997, Sanchez et al. 1997). Upon phosphorylation, 
the cdc25 phosphatase binds to 14-3-3 proteins, becomes sequestered in the cytoplasm 
and is degraded by the ubiquitin-proteasome pathway (C.-Y. Peng et al. 1997). It then 
leads to accumulation of Tyr15 phosphorylated Cdc2, a substrate for Wee1, that 
subsequently leads to mitotic arrest. Moreover, MAP kinases p38γ (X. Wang et al. 2000) 
and p38α (Bulavin et al. 2001) have been implicated in G2/M checkpoint response to IR 





Figure II-III Checkpoint signaling in response to DNA damage. 
In response to DNA damage, checkpoint kinases (ATR/ATM) get activated and initiate 
phosphorylation events to cause cell cycle arrest. Adapted from (Ashwell and Zabludoff 2008) 
 
II.4 Gemcitabine 
Gemcitabine (2’, 2’-difluorodeoxycytidine, dFdC) is a deoxycytidine analog having geminal 
fluorine atoms in the 2’-position of the sugar moiety (as depicted in Figure II-IV). This 
drug was found to be active in a broad spectrum of solid tumors, as a single agent in the 
treatment of pancreatic cancer (Burris et. al 1997), in combination chemotherapy of  
breast cancer (Albain et al. 2008), bladder cancer (von der Maase et al. 2000) and non-




                   
          
                          
      
 
Figure II-IV Structures of deoxycytidine and gemcitabine.  
Gemcitabine contains geminal fluorine atoms in the 2`-position of the sugar moiety. Adapted from 
(B Ewald, Sampath, and Plunkett 2008)  
 
Gemcitabine is a prodrug which requires cellular uptake and intracellular phosphorylation. 
Inside the cell, it is phosphorylated to the active metabolites- gemcitabine di- and 
triphosphate (dFdCDP and dFdCTP, respectively) (Heinemann et al. 1988). dFdCTP 
competes with dCTP for incorporation into the DNA (Huang et al. 1991); after 
incorporation of only one additional nucleotide by DNA polymerase into the DNA chain, it 
leads to termination of chain elongation. The nonterminal position of dFdCTP in the DNA 
chain prevents detection and repair by DNA repair enzymes (so-called masked chain 
termination) (Plunkett et al. 1995).These molecular events are critical for gemcitabine-
induced apoptosis.  
Efficient phosphorylation and relatively slow elimination ensures high build-up of dFdCTP 
and dFdCDP in cells. dFdCDP is a potent inhibitor of ribonucleotide reductase. 
Ribonucleotide reductase (RR) is the enzyme that mediates conversion of ribonucleotides 
to deoxyribonucleotides, which is the rate-limiting step in the DNA synthesis. Inhibition of 
RR impairs DNA synthesis and consequently affects cell proliferation, therefore, it is 
considered to be an important target for anticancer agents. dFdCDP is falsely recognized 
by RR as a natural substrate and leads to formation of abnormal products and 
subsequently to loss of RR catalytic activity. Inhibition of RR causes reduction of 
deoxynucleotide pools (Baker et al. 1991, van der Donk et al. 1998, Shao et al. 2006, J. 
Wang, Lohman, and Stubbe 2007). It is also possible that a change in the dFdCTP:dCTP 
ratio causes enhanced gemcitabine incorporation and further DNA synthesis inhibition, an 
action known as self-potentiation (Heinemann et al. 1990). Other reported activities of 




synthetase) (Heinemann et al. 1995) and deoxycytidylate deaminase (dCMP deaminase) 
by dFdCTP (Heinemann et al. 1992). It has recently been shown that gemcitabine can 
impede topoisomerase I, suggesting that induction of topoisomerase I-mediated DNA 
break formation can also contribute to the cytotoxicity of this drug (Pourquier et al. 2002). 
II.4.1 DNA damage response generated by gemcitabine 
Gemcitabine exerts its major cytotoxic effect through replication fork stalling, leading to 
activation of the ATR-Chk1 pathway that maintains genomic stability during replication 
stress. As discussed in section I.3.2.1, ATR is an essential replication checkpoint protein 
which gets activated upon replicative stress and further activates its downstream effector, 
Chk1. This activates the S-phase checkpoint which blocks cell cycle progression, down-
regulates origin firing and stabilizes replication forks (Paulsen and Cimprich 2007).  
II.4.2 Resistance towards gemcitabine in pancreatic cancer 
According to recent statistics, pancreatic cancer is the eighth leading cause of cancer-
related deaths in the world (Ferlay et al. 2010). Currently, gemcitabine is the leading 
therapeutic for pancreatic cancer as it improves the survival of patients; however the 
overall tumor response rate is only 5.4%, median survival duration of 5.65 months (Burris 
et. al 1997) and the median progression-free survival is 3.5 months (Moore et al. 2003). In 
many cases, pancreatic cancer develops resistance to the gemcitabine necessitating 
further studies into this aspect of cancer.  
Many genetic and/or epigenetic alterations have been found to be associated with 
gemcitabine resistance. These include gene products involved in- 
• Transport and metabolism of gemcitabine: Nucleoside transporter-1 (hENT1) is an 
important element involved in uptake of gemcitabine and its alteration provides 
gemcitabine resistance to pancreatic tumors (Giovannetti et al. 2006): Metabolic 
gene products: deoxycytidine kinase and ribonucleoside reductases M1 and M2 
have also been related to gemcitabine resistance (Nakano et al. 2007). 
• Cell survival or apoptosis: Aberrant expression of S100 can increase resistance 
partly by modulating hypoxia-induced proapoptotic gene, BNIP3 (Erkan et al. 
2005, Mahon et al. 2007). 
• Other pathways or proteins implicated in gemcitabine resistance include; 
phosphatidylinositol 3-kinase/Akt survival pathway (Ng et al. 2000, Ng et al. 2001, 
Bondar et al. 2002, Asano et al. 2004), activation of the non–receptor protein 
tyrosine kinases - focal adhesion kinase (M S Duxbury et al. 2004) and c-Src 




Apart from these factors, a plethora of regulators have also been found to decrease 
gemcitabine sensitivity of pancreatic cancer (Voutsadakis 2011). Consequently, if multiple 
individual genes contribute to resistance, it would require patient-specific, tailored 
treatment regimens using specific sensitizers based on the characterization of resistance 
mechanisms for individual tumors. Another strategy could be to define a `signature` 
resistant profile and target it to restore sensitivity, although patient-specific weightage of 
the variables would need to be taken into account in this case (M. P. Kim and Gallick 
2008). 
 
II.5 Targeting cell cycle checkpoint kinases in combination with 
gemcitabine 
Cancer cells can evade the normal physiological signals for growth and survival by 
deregulation of kinases. This being one of the major mechanisms for the cancer cell 
proliferation and survival, has attracted many researchers to design small molecules that 
target and inhibit kinases (J. Zhang, Yang, and Gray 2009). Checkpoint kinases have 
emerged as therapeutically important targets as their inhibition could selectively sensitize 
cancer cells to DNA-damaging agents, thus potentiating the anti-tumor activity and 
widening the therapeutic margin of these agents. In majority of cancer cells, G1 
checkpoint is impaired; as a consequence, these cells rely on S- and G2/M-phase 
checkpoints for DNA repair and survival (Ashwell and Zabludoff 2008). The known players 
involved in S- and G2/M- phase checkpoints are ATR, Chk1 and Wee1. Thus,  combining 
inhibitors of these kinases with gemcitabine can sensitize different tumor cells; which 
includes pancreatic, colon and breast tumors (Prevo et al. 2012a), Zabludoff et al. 2008, 
(Rajeshkumar, Oliveira, et al. 2011). Since gemcitabine leads to replicative stress in the 
cells and activates the S-phase checkpoint to counteract the damage to DNA, inhibitors of 
checkpoint kinases can allow the cells to move through the S-phase even when DNA is 
not repaired, thus pushing the cells towards cell death.  
 
II.6 The kinase Wee1 – a regulator of Cdks  
Wee1 is a nuclear protein and a serine/threonine and tyrosine kinase which negatively 
regulates the activity of Cdks by phosphorylating them at Tyr15 (Parker and Piwnica-
Worms 1992) and hence, controls the cell cycle progression. The protein levels and 
activity of Wee1 are tightly regulated during cell cycle; they peak during S- and G2- 




hyperphosphorylation and degradation of Wee1 has been observed (N Watanabe, 
Broome, and Hunter 1995). At the onset of mitosis, Wee1 is phosphorylated by cdc2 (or 
cdk1) and Polo-like kinase1 (Plk1) at Ser123 and Ser53; these phosphorylation sites are 
recognized by the SCFβ-TrCP1/2, an E3 ubiquitin ligase, for Wee1 ubiquitination 
(Nobumoto Watanabe et al. 2004).  
 
Figure II-V Primary structure of the human Wee1 protein.  
The NRD, kinase domain, and short carboxy-terminal domain are marked, with border amino acid 
residues numbered (below). The T239 Cdk phosphorylation site, an inhibitory modification, resides 
within the Wee box, a positive regulatory element. Adapted from (Enders 2010) 
 
Several other kinases have also been reported to phosphorylate and activate Wee1. In 
Xenopus, it has been shown that 14-3-3 binds to Wee1; this requires prior 
phosphorylation at Ser549 near the C-terminus of Wee1; Chk1 was shown to 
phosphorylate Ser549 (Ser642 in human Wee1). In contrast, in humans, it has been 
suggested that other kinases may play this role (J. Lee, Kumagai, and Dunphy 2001, 
Rothblum-Oviatt, Ryan, and Piwnica-Worms 2001). Wee1 is also positively regulated by 
autophosphorylation- three sites on the Xenopus Wee1 (Tyr90, Tyr103 and Tyr110) and 
two sites on the human Wee1 (Tyr295 and Tyr362) have been identified as 
autophosphorylation sites (Murakami, Copeland, and Vande Woude 1999, Katayama, 
Fujita, and Tsuruo 2005). Moreover, it has been reported that the activity of Wee1 can 
also be stimulated by the Cdk-interacting protein Cables (C. L. Wu et al. 2001). 
DNA damage (e.g., radiation or UV irradiation) activates Chk1, which promotes G2/M 
arrest through phosphorylation of Cdc25C and Wee1. Cdc25C is a phosphatase that 
dephosphorylates Tyr15 of Cdc2 and thus, activates it (A Kumagai and Dunphy 1991). 
Cdc25C is phosphorylated on Ser216 by Chk1 and the phosphorylated form of Cdc25C 
binds to 14-3-3 and eliminates its functions through translocation to the cytoplasm (C. Y. 
Peng et al. 1997). Moreover, Chk1 may also phosphorylate Wee1 at Ser642. Although it 
is not yet reported in humans, phosphorylated Ser642 increases the stability of Wee1 in 




screening (J. Lee, Kumagai, and Dunphy 2001, Y. Wang et al. 2000). As a result, Cdc2 is 
continuously phosphorylated at Tyr15, and the cell cycle arrests at the G2/M transition. 
This way, the balance between Cdc25 and Wee1 is tightly controlled through the cell 
cycle so that cells undergo G2/M transition without damaged DNA. 
II.6.1.1 Inhibition of Wee1 and genomic instability in cancer 
Wee1 depletion has been found to induce replicative stress. Inhibition of Wee1 kinase 
elevates Cdk activity that rapidly increases initiation of replication. Firing of replication 
origins is increased, followed by shortage of nucleotides and reduction in replication fork 
speed, and subsequent generation of DNA double-strand breakage mediated by 
SLX4/MUS81. Interestingly, depletion of a key factor for replication initiation, known as 
CDT1, leads to normalized fork speed and suppressed DNA DSB formation. Furthermore, 
addition of nucleosides counteracts the effects of unscheduled Cdk activity on fork speed 
and DNA DSB formation (Beck et al. 2012).  
It has been shown that cells arrested in S-phase enter directly into mitosis without 
completely replicating DNA when Wee1 is inhibited in these cells (also known as 
premature mitosis). This results in highly unusual mitoses identified by scattered 
chromosomes and disordered spindle fibers, which eventually leads to exit of cells from 
mitosis with many micronuclei formation and apoptosis (Aarts et al. 2012). When cells 
enter into mitosis prematurely with unrepaired lethal DNA damage, it results in mitotic 
catastrophe. Thus, Wee1 inhibition pushes the cells to mitotic catastrophe when 
combined with DNA-damaging agents, especially in p53 deficient cancer cell (Hamer et 
al. 2011). 
II.6.1.2 Mitotic catastrophe versus apoptosis 
Mitotic catastrophe (MC) is the process resulting from abnormal or premature mitosis and 
is characterized by the formation of multinucleated cells and leads to cell death. Cell 
death could occur by apoptosis or necrosis either during or after dysregulated mitosis. 
When cells enter into mitosis, histone 3 (H3) gets phosphorylated at Ser10 and plays a 
part in complex signaling network and besides serve as mitotic marker (Hans and 
Dimitrov 2001, Tsuta et al. 2011). Alternately, mitotic cells can be stained with MPM-2 
anitbody (mitotic phosphoprotein monoclonal antibody 2), this antibody recognize a 
subset of proteins having mitotically phosphorylated S/TP motifs (peptides containing 
LTPLK and FTPLQ domains) (C. F. Wu et al. 2010). Cells undergoing premature mitosis 
stain positive for the above mentioned mitotic markers and can be identified using flow 
cytometry; this gives a quantifiable indication of cells going through MC. MC is considered 
to prevent genomic instability in the cells and its disruption promotes tumorigenesis and 




Apoptosis is the process of programmed cell death and is one of the modes of removing 
damaged cells and thus, help prevent tumorigenesis. Cells undergoing apoptosis are 
characterized by chromatin condensation, extensive plasma membrane blebbing and 
nuclear fragmentation. Apoptotic cells are afterwards phagocytosed by macrophages, 
parenchymal cells, or neoplastic cells and degraded within phagolysosomes (Elmore 
2007). Several apoptotic pathways in cells responsive to apoptotic stimuli have been 
suggested, such as the death receptor–mediated pathway, the mitochondrial apoptotic 
pathway, and the endoplasmic reticulum pathway. Although initial induction mechanisms 
are different for each pathway, they converge at a common final phase of apoptosis, 
consisting of the activation of the executioner caspases and cleaving of substrates critical 
for cell survival. It has been reported that in response to chemotherapeutic treatment, 
mitochondrial pathway is largely activated wherein permeability of mitochondrial 
membrane is increased resulting in release of apoptotic components such as cytochrome 
c, apoptosis-inducing factor (AIF) and endonuclease G. These proteins eventually 
activate caspase which leads to cell death. However, mammalian cells can undergo 
caspase-independent apoptosis under certain circumstances. Caspase-independent 
apoptosis is mediated by the disruption of the mitochondrial membrane potential and the 
translocation of AIF and endonuclease G to the nucleus where they induce chromatin 
condensation and/or large-scale DNA fragmentation (T.-J. Lee et al. 2006).  
II.6.1.3 Integration of mitotic catastrophe and apoptosis 
In some instances, MC is accompanied by the hallmarks of apoptosis suggesting the 
interaction of checkpoints or sensors of mitotic failure and apoptotic machinery (Castedo 
et al. 2006). During metaphase-arrest, Cdk1 can phosphorylate anti-apoptotic proteins, 
such as Bcl-xl (a member of Bcl-2 protein family) (Terrano, Upreti, and Chambers 2010) 
and survivin (Barrett, Osborne, and Wheatley 2009) and inhibit their activity, thereby 
facilitating cell death. In addition to metaphase arrest-induced apoptosis, tetraploid cells 
that are generated through catastrophic mitosis followed by mitotic slippage also undergo 
apoptosis. It is evidenced by an immediate induction of p21 after mitotic slippage, which is 
an indicator of a p53-dependent checkpoint response in G1-phase (Vogel et al. 2004). 
Apoptosis, however, is not always required for MC lethality, as some multinucleated cells 
can undergo slow death in a necrosis-like manner (Eom et al. 2005). 
 
II.7 Polo-like kinase1 and its role in ATR-Chk1 pathway 
Polo-like kinases (Plks) are emerging as key regulators of essential cell cycle events. Plk 




this family contain an N-terminal Ser/Thr kinase catalytic domain and a C-terminal region 
containing two conserved Polo-box regions. Plk1 localizes to the cytoplasm and 
centrosome during interphase and concentrates to kinetochores and the cytokinesis 
bridge during cell division. Thus, it plays a major role in centrosome maturation, mitotic 
entry, and cytokinesis (Archambault and Glover 2009). The Polo-box domain (PBD) of 
Plk1 plays a unique role in subcellular localization and mediates protein interactions 
(Cheng et al. 2003, Elia et al. 2003). It is a phospho-peptide binding domain that binds to 
the proteins ‘primed‘ or phosphorylated by kinases, thereby facilitating localization of Plk1. 
Kinases known to prime Plk1 substrates include Cdk1, that drives the cells into mitosis (K. 
S. Lee et al. 2008). Plk1 activity is also regulated by Aurora A kinase through an auxiliary 
protein, Bora (Seki et al. 2008). As shown in Figure II-VI, binding of Bora to Plk1 facilitates 
the phosphorylation of Plk1 at Thr210 by Aurora A causing the activation of Plk1. 
Plk1 has been identified as a novel modulator of DNA damage checkpoints, where it 
maintains genomic stability during DNA replication (Takaki et al. 2008). It facilitates 
recovery from DNA damage checkpoint-mediated arrest at G2/M phase following 
successful DNA damage repair (Niels Mailand et al. 2006, van Vugt, Brás, and Medema 
2004). After DNA damage, phosphorylation of Thr210 of Plk1 is inhibited that targets Plk1 
for degradation by the anaphase-promoting complex/cyclosome (APC/C) bound to its 
activator Cdh1; this prevents entry of the cells into mitosis. It has been found that 
successful resumption of cell cycle progression at G2/M and mitotic entry relies on the 
activation of Plk1 by Aurora A/Bora-mediated phosphorylation of Thr210 within the 
activation loop of Plk1 (Macůrek et al. 2008, Seki et al. 2008). Subsequently, Plk1 induces 
degradation of Wee1, a kinase that inhibits Cdk1 (van Vugt, Brás, and Medema 2004), 
and Claspin, an adaptor protein that is required to sustain Chk1 and checkpoint activity 
(Niels Mailand et al. 2006a), Mamely et al. 2006). Phosphorylation of a sequence in 
Claspin's amino-terminus, called phosphodegron, by Plk1 marks Claspin for degradation 
by the SCFβ-TrCP1/2 ubiquitin ligase. Elimination of Wee1 and Claspin contributes to 
Cdk1 activation and leads to mitotic entry. 
 




B.            
Figure II-VI A. Structure of human Plk1.  
The positions of the kinase domains (red) and polo-boxes 1 and 2 (blue) are also depicted. The 
PLK1 sequences that mediate its nuclear localization (NLS, which is indicated in green) and its 
destruction at the end of mitosis (D-box, which is indicated in yellow) are also shown. Residues 
that are crucial for ATP-binding and enzymatic activation (T-loop) within the kinase domains, and 
phospho-selectivity within the polo-boxes are indicated. Adapted from (Strebhardt and Ullrich 
2006) 
 
B. Priming of Bora by Cdk1 for Plk1 activation by Aurora A.  
Cdk1 phosphorylates Bora, which is recognized by Plk1. Plk1 undergoes a conformational change 
and Thr210 is exposed to be phosphorylated by Aurora A. This phosphorylation, in turn, activates 
Plk1. Adapted from (K. S. Lee et al. 2008) 
 
Interestingly, it has been shown that DNA damage checkpoints can regulate signaling 
pathways upstream of Plk1. Plk1 is phosphorylated at Ser137 and Thr210 during mitosis, 
and phosphorylation at these sites is prevented during DNA damage through ATR/ATM-
dependent signaling pathways in asynchronous cells (Tsvetkov and Stern 2005). 
 
II.8 Nutlin- 3, as a protector of p53-proficient cells against 
nucleoside analogues 
p53 is a tumor suppressor protein that prevents the propagation of DNA damage which 
may lead to malignant cell transformation (Levine 1997, B Vogelstein, Lane, and Levine 
2000). As discussed in section I.4.3, p53 levels are tightly controlled by its negative 
regulator, Mdm2 that binds to p53 and modulates its transcriptional activity and stability 
(Oliner et al. 1993, Freedman, Wu, and Levine 1999). Upon DNA damage, Mdm2 levels 
fall and p53 levels increase, which induces G1 arrest that is mediated by its immediate 




Nutlin-3 is a small molecule inhibitor of Mdm2-p53 interaction, thereby, causing non-
genotoxic accumulation of p53 which results in cell cycle arrest and/or apoptotic response 
(Miyachi et al. 2009). Nutlin-3 has been found to selectively activate wild-type p53 and not 
mutant p53. This differential activity of Nutlin-3 can be utilized to protect the normal 
proliferating cells (having wild-type p53) from cytotoxicity of mitotic inhibitors or S-phase 
specific chemotherapeutics used to treat tumor cells (either p53-deficient or having 
mutant p53) (Carvajal et al. 2005). Due to the tumor suppressive role of p53, it is mutated 
in about 50% of human tumors rendering them insensitive to p53- activating agents (B 
Vogelstein, Lane, and Levine 2000, Hollstein et al. 1991). This provides the opportunity to 
develop an improved strategy for protection of normal proliferating tissues without 
affecting the sensitivity of tumors with mutant p53 to certain chemotherapeutics. It has 
been shown that pretreatment with nutlin before chemotherapy with antimitotic agents 
(paclitaxel) and S-phase abrogators (gemcitabine) can offer partial protection to normal 
proliferating tissues by causing cell cycle arrest in G1 and G2-M phase (Carvajal et al. 
2005, Kranz and Dobbelstein 2006). 
 
II.9 Scope of the thesis 
Combining checkpoint inhibitors with gemcitabine provides a promising way of sensitizing 
tumors. However, there are no studies which compare quantitatively the efficacy of the 
inhibition of different checkpoint kinases with gemcitabine. In this project, we have tried to 
address this question and the questions arising from it. 
Inhibition of Wee1 checkpoint kinase sensitizes tumor cells towards the chemotherapeutic 
drug, gemcitabine. Various studies have been performed to determine how Wee1 
inhibition in combination with gemcitabine could lead to enhanced cytotoxicity. Here, we 
asked whether Wee1 inhibition interferes with the activity of additional checkpoint kinases, 
thereby enhancing cytotoxicity.   
Nutlin can act as protector for normal proliferating cells against gemcitabine while it does 
not affect the sensitivity of tumor cells with mutant p53 towards chemotherapy. Still, the 
protective role of Nutlin has not been analyzed for combinations of gemcitabine with 
checkpoint kinase inhibitors. We therefore asked whether nutlin pretreatment, protects 





III.1 Technical devices 
Table III.1-1 Technical Devices 
Device Company 
Blotting chamber  Biozym, Hessisch Oldendorf, Germany 
Cell counting chamber Neubauer improved Brand, Wertheim, Germany 
Centrifuge 5415R Eppendorf, Hamburg, Germany 
Centrifuge 5810R Eppendorf 
Centrifuge Megafuge 1.0R Heraeus, Thermo Scientific, Waltham, MA, 
United States 
Chemiluminescence imager Chemocam HR 
16 3200 
Intas Science Imaging Instruments, 
Göttingen, Germany 
Cytometer Celigo Cyntellect, San Diego, CA, United States 
DNA gel chamber Biotech Service Blu, Schauenburg, 
Germany 
Electrophoresis system, for SDS-PAGE Amersham Biosciences, GE Healthcare, 
Little Chalfont, United Kingdom 
FACS machine  Guava PCA-96 Base 
System 
FACS machine  FACScanto II 
Millipore, Merck, Darmstadt, Germany 
 
Becton Dickinson, Franklin Lakes, NJ, 
United States 
Foil swelding machine Vacupack plus Krups, Groupe SEB, Lyon, France 
Freezer -20°C Liebherr, Bulle, Switzerland 
Freezer -80°C Heraeus, Thermo Scientific 
Heating Block Grant Instruments, Hillsborough, NJ, United 
States 
Heating Block HLC HLC Biotech, Ditabis, Pforzheim, Germany 
Ice-machine B100 Ziegra, Isernhagen, Germany 
Incubator for cell culture Hera Cell 150 Heraeus, Thermo Scientific, Waltham, MA, 
United States 
Laminar flow cabinet Hera Safe Heraeus, Thermo Scientific 
Liquid nitrogen tank LS 4800 Taylor-Wharton, Theodore, AL, United 
States 
Magnetic stirrer MR Hei-Standard Heidolph, Schwabach, Germany 
Magnetic stirrer MR3001 Heidolph 
Microscope Axiovert 40C Zeiss, Oberkochen, Germany 
Microscope, automated Pathway 855 Becton Dickinson, Franklin Lakes, NJ, 
United States 
Microscope, confocal Zeiss Confocal LSM 
510 meta 
Zeiss 
Mini Centrifuge MCF-2360 
Multichannel Pipette Transferpette S-8  
LMS, Tokyo, Japan 
BrandTech Scientific, Inc 
PCR machine for qPCR CFX96, C1000 Bio-Rad Laboratories 
PCR machine Thermocycler T personal Biometra, Göttingen, Germany 
Personal computer Dell, Round Rock, TX, United States 
pH-meter WTW-720 WTW, Weilheim, Germany 
Pipets Eppendorf Research Series 2100 
(0.1-2.5μL; 2-20μL; 20-200μL; 100-1000μL) 
Eppendorf 
Power supply unit Powerpack P25T Biometra 




Roller RM5 V-30 CAT, Staufen, Germany 
Scales Acculab ALC-6100.1 Sartorius, Göttingen, Germany 
Scales LE623S Sartorius 
Scanner CanoScan 8600F Canon, Tokyo, Japan 
Shaker PROMAX 2020 
Shaker POLYMAX 2040 




Sonication device Bioruptor Diagenode, Liège, Belgium 
Spectrophotometer NanoDrop ND-1000 PeqLab, Erlangen, Germany 
Thermomixer comfort Eppendorf 
Timer  Oregon Scientific, Portland, OR, United 
States 
Vacuum pump IBS Integra Biosciences, Fernwald, 
Germany 
Vortex Genie 2 Scientific Industries, Bohemia, NY, United 
States 




Table III.2-1 Consumables 
Product Company 
96-well plates for microscopy, clear bottom Becton Dickinson 
96-well plates for microscopy, clear bottom Corning, Corning, NY, United States 
96-well plates for qPCR 4titude, Wotton, United Kingdom 
Cell culture dishes (10 cm, 15 cm) Greiner, Frickenhausen, Germany 
Cell culture plates (6-well, 12-well) Greiner 
Cell scraper (16 cm, 25 cm) Sarstedt 
Cover slips Menzel, Thermo Scientific 
Cryo tubes Cryoline Nunc, Thermo Scientific 
Filter tips (10 µL) Starlab, Hamburg, Germany 
Filter tips (20 µL, 200 µL, 1,000 µL) Sarstedt 
Glass Slides Superfrost Menzel, Thermo Scientific 
Parafilm Brand 
Pipet tips (10 µL, 20-200 µL, 1,000 µL) Greiner 
Protran nitrocellulose transfer membrane Whatman, Dassel, Germany 
PVDF membrane Amersham Hybond-P GE Healthcare, Life Sciences 
Reaction tube (0.2 mL) Sarstedt 
Reaction tube (0.5 mL, 1.5 mL, 2.0 mL) Eppendorf 
Reaction tube (15 mL, 50 mL) Greiner 
Sealing foil for 96-well plate Thermo Scientific 
Sterile filter Millipore, Merck 
Syringe Henke-Sass, Wolf, Tuttlingen, Germany 
Syringe canula (different sizes) B.Braun, Melsungen, Germany 
Transparent sealing foil for 96-well plate 4titude 







III.3 Chemicals and reagents 
Table III.3-1 Chemicals and reagents 
Substance Company 
Acetic acid Roth, Karlsruhe, Germany 
Agarose Roth 
Albumin Fraction V (Bovine Serum Albumine, 
BSA) 
Roth 
Ammonium persulfate (APS) Roth 
Ammonium sulfate ((NH4)2SO4) Roth 
Ampicillin AppliChem, Darmstadt, Germany 
Bromophenol blue Sigma-Aldrich 
Calcium chloride dihydrate (CaCl2 x 2H2O) Roth 
Chloroform Roth 
Complete Mini Protease Inhibitor Roche, Basel, Schweiz 
Dimethyl sulfoxide (DMSO) AppliChem 
Dithiotreitol (DTT) Sigma-Aldrich 
DNA ladder Fermentas, Thermo Scientific 
deoxynucleotide triphosphates (dNTPs) Bio-Budget, Krefeld, Germany 
Ethanol 99.8% Roth 
Ethanol 99.9% p.a. (EtOH) Merck 
Ethidium bromide (EtBr) Sigma-Aldrich 
Ethylene diamine tetraacetatic acid (EDTA) Roth 
Formaldehyde, 37% solution Roth 
Glycerine Roth 
Glycine Roth 
Glycogen blue Ambion, Life Technologies 
Guava ICF Cleaning Solution Millipore, Merck 
HEPES Roth 
Hoechst 33342 (Hoechst) Invitrogen, Life Technologies 
Hydrogen chloride (HCl) Roth 
Immersion oil Zeiss 
Isopropanol Th. Geyer, Renningen, Germany 
Lipofectamine 2000 Invitrogen, Life Technologies 
Magnesium chloride (MgCl2) for PCR Fermentas, Thermo Scientific 
Magnesium chloride hexahydrate (MgCl2 x 
6H2O) 
Roth 
Methanol >99% (MetOH) Roth 
Nailpolish  
Nonidet P-40 substitute (NP-40) Sigma Aldrich 
Nuclease free water Ambion, Life Technologies 
Ponceau S Roth 
Potassium chloride (KCl) Roth 
Potassium hydrogenphosphate (KH2PO4) Roth 
Prestained Protein Ladder Fermentas, Thermo Scientific 
Propidium iodide (PI) Sigma-Aldrich 
Protein-G-Sepharose (PGS) 4Fast Flow GE healthcare 
RNase inhibitor Fermentas, Thermo Scientific 
Rotiphorese Gel 30 Roth 
Sodium bicarbonate (NaHCO3) Roth 
Sodium chloride (NaCl) Roth 








Sodium hydrogenphosphate heptahydrate 
(Na2HPO4 x 7H2O) 
Roth 
Sodium hydroxide (NaOH) Sigma-Aldrich 
Sodium orthovanadate 




SYBR green Invitrogen, Life Technologies 
Tetracycline Sigma-Aldrich 
Tetramethylethylenediamine (TEMED) Roth 
Thymidine Sigma-Aldrich 
Trasylol Bayer, Leverkusen, Germany 
Trehalose Sigma-Aldrich 
Trisamine (Tris) Roth 
Triton X-100 Applichem 
Trizol Invitrogen, Life Technologies 
Tween 20 Applichem 
Vectashield mounting medium Vector Laboratories, Burlingame, CA, 
United States 
 
III.4 Buffers and solutions 
Cell lysis buffer 
Urea 
RIPA lysis buffer 
2.5 M 
100% 













IF blocking solution 
BSA 
dissolved in PBS 
3% 
IP buffer 















Laemmli buffer, 6x 













Phophate buffered saline (PBS), pH 7.5 
NaCl 
KCl 
Na2HPO4 x 7H2O 
KH2PO4 









Na2HPO4 x 7H2O 
KH2PO4 
CaCl2 x 2H2O 
MgCl2 x 6H2O 








Ponceau S solution  
Ponceau S 
Acetic acid 










qPCR reaction buffer, 10x 
Tris, pH 8,8 750 mM 
(NH4)2SO4 200 mM 
Tween 20 0.1% 
dissolved in H2O  
 
 
qPCR reaction mix, 25x 







Trehalose in 10 mM 








Dissolved in H2O  
 






Tris, pH 7.5 
Trasylol 



























Tris buffered saline + Tween 20 









Western blot blocking solution 
BSA 
dissolved in TBST 
5% 
 
















III.5 Chemotherapeutics and pharmacological inhibitor 
Table III.5-1 Chemotherapeutics 
Name Systematic name Company 
Gemcitabine 2',2'-difluorodeoxycytidine (dFdC) Eli Lilly, Indianapolis, IN, 
United States 
 
Table III.5-2 Inhibitors 
Inhibitor Commercial name Target Company 




Chk1i  SB-218078 Chk1 Calbiochem, Merck 
Nutlin-3 Nutlin-3 Mdm2 Sigma-Aldrich 
Plk1i GSK-461364 Plk1  
Roscovitine Roscovitine Cdk1, 2 and 5 Cell Signaling 
RO-3306 RO-3306 Cdk1 Sigma-Aldrich 
Wee1i MK-1775 Wee1 Selleck 
    
 
 
III.6 Enzymes and buffers 
Table III.6-1 Enzymes and buffers 
Reagent Company 
Buffer for M-MuLV RT, 10x New England Biolabs, Ipswich, MA, United 
States 
Buffer for Taq with KCl, 10x Fermentas, Thermo Scientific 
Buffer R Fermentas, Thermo Scientific 
M-MuLV Reverse transcriptase (RT) New England Biolabs 
RNase A Qiagen, Venlo, Netherlands 




Table III.7-1 Kits 
Name Company 
Guava Check Kit Millipore, Merck 
Immobilon Western HRP Substrate Peroxide Solution  Millipore, Merck 
PureYield Plasmid Midiprep System Promega 
SuperSignal West Femto Maximum Sensitivity Substrate Thermo Scientific 
 
III.8 Oligonucleotides 
Table III.8-1 Small interfering RNAs 
Name (identifies target) siRNA ID 
Negative Control No. 1 Undisclosed  







Chk1 #2 s503  
Wee1 #1 s21  
Wee1 #2 s22  
Mus81 s37038  
Claspin #1 s34330 





All siRNAs are Silencer Select from Ambion, Life Technologies.  
 
Table III.8-2 Primers 
Name Sequence Application 
anchored oligo-dT dT23VN RT-PCR 
random nonamer 5’-NNNNNNNNN-3’ RT-PCR 
36B4 forward 5’-GATTGGCTACCCAACTGTTG-3’ 
qPCR 
36B4 reverse 5’-CAGGGGCAGCAGCCACAAA -3’ 
ATR forward 5’-CATGCTAACAGGTCCGAGT -3’ 
qPCR 




Table III.9-1 Primary antibodies 
Target Clone Source organism 
Dilution for 
immunoblotting Company 
ATR N-19 goat 1:300 Santa Cruz Biotechnology, 
Santa Cruz, CA, United States 
ATR pT1989  rabbit 1:300 Kerafast 
Cdc2 POH-1 mouse 1:2,000 Cell Signaling Technology, 
Beverly, MA, United States 
Cdc2 pY15  rabbit 1:1,000 Abcam 
Chk1 2G1D5 mouse 1:1,000 Cell Signaling Technology 
Chk1 pS317  rabbit 1:1,000 Cell Signaling Technology 
Claspin  rabbit 1:1,000 Cell Signaling Technology 
H2AX pS319 JBW301 mouse 1:4,000 Millipore, Merck 
H2AX pS319  rabbit 1:1,000 Cell Signaling Technology 
H3 pS10 (D2C8) 
XP 
rabbit 1:1,600 Cell Signaling Technology 
HSC70 B-6 mouse 1:15,000 Santa Cruz Biotechnology 
Mus81 MTA30 
2G10/3 
mouse 1:500 Santa Cruz Biotechnology 
Mdm2 (Ab-1), 
IF-2 
mouse 1:300 Calbiochem 
p21 (Ab-1) 
EA10 
mouse 1:500 Calbiochem 
p53 DO-1 mouse 1:1,000 Santa Cruz Biotechnology 
PARP  rabbit 1:1,000 Cell Signaling Technology 
Plk1 35-206 mouse 1:1,000 Life Technologies 




Rad17 H-3 mouse 1:1,000 Santa Cruz Biotechnology 
Rad17 pS645 D5H5 rabbit 1:1,000 Cell Signaling Technology  
Wee1  rabbit 1:1,000 Cell Signaling Technology 
β-Actin AC-15 mouse 1:20,000 Abcam 
 
 
Table III.9-2 Secondary antibodies 
Antibody Cat. Number Company 
Alexa-Fluor-488 goat anti rabbit A-11034  Invitrogen, Life Technologies 
Alexa-Fluor-546 goat anti mouse A-11003  Invitrogen, Life Technologies 
Alexa-Fluor-594 goat anti mouse A-11005 Invitrogen, Life Technologies 
HRP-coupled AffiniPure F(ab')2 
fragment, anti-mouse IgG (H+L)  
711-036-152  Jackson Immunoresearch, 
Europe, Newmarket, UK 
HRP-coupled AffiniPure F(ab')2 
fragment, anti-rabbit IgG (H+L)  
715-036-150  Jackson, Immunoresearch  
HRP-coupled AffiniPure, anti-goat        115-035-044          Jackson, Immunoresearch 
 
III.10 Human cell culture 
Table III.10-1 Human cell lines 
Cell line Origin 
BxPC-3 Pancreatic adenocarcinoma 
HCT116 (wild-type p53/ p53-/-) Colorectal carcinoma 
HeLa Cervical adenocarcinoma 
MCF7 Breast adenocarcinoma 
MIA PaCa-2 Pancreatic adenocarcinoma 
PANC-1 Pancreatic epithelioid carcinoma 
U2OS Osteosarcoma 
 
Table III.10-2 Media and reagents for eukaryotic cell culture 
Reagent Company 
Ciprofloxacin Bayer 
Dulbecco’s Modified Eagle Medium (DMEM), powder Gibco, Life Technologies 
DMEM, High Glucose, Phenol-Red Free Gibco, Life Technologies 
Fetal Calf Serum (FCS) Gibco, Life Technologies 
L-Glutamine Gibco, Life Technologies 
McCoy’s Medium  Gibco, Life Technologies 
PBS (tablets) Gibco, Life Technologies 
Penicillin/Streptomycin Gibco, Life Technologies 
Tetracyclin Gibco, Life Technologies 







DMEM, powder 10.0 g 
NaHCO3 3.7 g 
HEPES 5.96 g 
dissolved in H2O 
 
III.11 Software 
Table III.11-1 Software 
Name Company 
BD Pathway Software  Becton Dickinson 
Celigo Software  Cyntellect 
CFX Manager Software for 
qPCR cycler  
Bio-Rad 
Excel Microsoft, Redmond, WA, United States 
Guava Express Software  Millipore, Merck 
INTAS lab ID  Intas Science Imaging Instruments 
NanoDrop Software Peqlab 





















IV.1 Cell Biology Techniques 
IV.1.1 Culturing of Human cancer cell lines 
All the cell culture work was performed under the hood in sterile conditions. 1X PBS, 0.1% 
trypsin/EDTA and medium were pre-warmed prior to use. 
Cell lines were adherent and cultured either in sterile tissue culture petri-dishes or flasks 
with suitable media. Media of the cell lines was supplemented with 10% FCS, 200µM L-
glutamine and antibiotics – 50U/ml Penicillin and Streptomycin, 20µg/ml Tetracycline and 
10µg/ml Ciprofloxacin; depending on the tolerance capacity of the cell lines (Table IV.1-1).
  
Table IV.1-1 Media for different cell lines 
Cell lines Media Supplements 
U2OS (Osteocarcinoma) DMEM All 
Panc1 (Pancreatic tumor) DMEM All 
MiaPaCa2 (Pancreatic 
tumor) 
DMEM All except Ciprofloxacin and Tetracycline 
BxPC3 (Pancreatic tumor) DMEM All except Ciprofloxacin and Tetracycline 
MCF7 (Breast tumor) DMEM 
(high 
glucose) 
All except Glutamine, Ciprofloxacin and 
Tetracycline 
HeLa (Cervical cancer) DMEM All 
HCT116 wild type p53 Mc Coy´s  All except Tetracycline 
HCT116 p53-/- Mc Coy´s  All except Tetracycline 
 
For the maintenance of cell lines in cell culture, they were stored at 37°C, 5% CO2 in 
humidified conditions. For sub-culturing, cells were washed with 1X PBS to remove dead 
cells, trypsinized and upon detachment of the cells from the surface of the petri-dish, 
medium was added to stop the reaction. Cells were then re-seeded in the appropriate 




IV.1.2 Freezing of cells 
Cells with low passage number were frozen for long-term storage. Freezing medium was 
prepared using FCS and DMSO in the ratio of 9:1. It was allowed to cool. Cells were 
washed and trypsinized, followed by addition of media to stop this reaction. Cells were 
then centrifuged at 1000 rpm for 5min, media was removed, and they were re-suspended 
in freezing medium and immediately transferred to cryotubes (on ice). They were first 
stored at -80°C for 24 h and transferred to liquid nitrogen afterwards. 
From a large dish (25 cm), 3-4 aliquots of 1 ml can be prepared. 
IV.1.3 Thawing of cells 
Frozen cells were thawed at 37°C for a few seconds and added into medium. They were 
centrifuged at 1000 rpm for 5 min, resuspended in fresh medium and seeded in a 10 cm 
petri-dish. Medium in the plate was changed after 24 h. 
Cells were used for transfection after passaging 3-4 times. 
IV.1.4 Transfection of cells with siRNA 
To knockdown specific gene of interest, reverse transfection was performed wherein cells 
were seeded on the same day as transfection mix was added. 
Cells were washed with 1X PBS, trypsinized and afterwards media was added to make a 
cell suspension.  Cells were counted on a Neubauers chamber slide. 
Using following formula, concentration of cells was calculated: 
Concentration of cells (cells/ml) = Number of cells X 10,000 











siRNA and Lipofectamine (LF2000) were diluted in the medium (without medium) as 
mentioned in the Table IV.1-2. 













96 well 8,000 25 4,5 pmol (silencer siRNA) 14,75 0,25 
96 well 8,000 25 1,5 pmol (silencer select 
siRNA) 
14,75 0,25 
12 well 1,00,000 100 1 µl (50 pmol) 100 2 
6 well 1,60,000-
2,00,000 
200 2 µl (100 pmol) 200 4 
*Cell number can vary depending on the cell line. 
Diluted Lipofectamine was incubated for 5 min at room temperature; appropriate amount 
of it was then mixed with diluted siRNA and incubated for 20 min. After incubation, siRNA-
lipofectamine mix was pipetted into the wells, followed by addition of suitable amount of 
cells from cell suspension. 
Media was changed after 24 h and depending on the experimental setup; cells were 
either harvested or treated with required chemicals or drugs. 
IV.1.5 Chemical or drug treatment  
Stock solutions of the chemicals or drugs were prepared either in water or DMSO. 
Required amount from stock solution was dissolved in medium to get the final 
concentration as outlined in the Table IV.1-3. 
Table IV.1-3 Concentration of chemicals or drugs used in the treatment 




SB 218078 Chk1 DMSO 2.5 mM 2.5 µM/ 5 µM 
VE-821 ATR DMSO 10 mM 10 µM/ 5 µM 
MK-1775 Wee1 DMSO 1 mM 1 µM/ 0.5 µM 
Roscovitine CDK1,-2 and -5 DMSO 20 mM 20 µM 
RO-3306 CDK1 DMSO 10 mM 10 µM 
GSK 461364 Plk1 DMSO 10mM 100nM 











Gemcitabine Water 64 mM 300 nM/ 25 nM/  
5 nM 
 
IV.1.6 Cell proliferation assay 
To monitor the health and growth rate of the cells, the fundamental tool is to assess the 
proliferative activity of the cells grown in culture. To track the cell proliferation Celigo cell 
cytometer was used; it can be used to measure the confluency or perform direct cell 
counting of the cells in the plates (compatible with the instrument). It provides a non-
destructive, label-free and automated way of measuring the cell growth upon desired 
treatment of the cells. 
This assay was utilized to ensure the growth of the cells when treated with inhibitors of 
Wee1/ Chk1/ ATR with or without gemcitabine. Cells were seeded in 96- well plate, 
treated after 18-24 h and the confluency of the cells was measured (labeled as Day0). 
After 24 h, media was replaced with fresh media; measurement was taken (Day1) and 
subsequent measurements were made after every 24 h and media was changed after 48 
h. Once required amount of measurements were taken, confluency was plotted against 
time (in days) using Microsoft Excel. 
 
IV.1.7 Protein Chemistry Techniques 
IV.1.8  Preparation of whole cell lysates 
Cell lysate preparation was done on ice. Cells adherent to the surface of the plate were 
scraped off into the medium and transferred into an Eppendorf tube. Cells were pelleted 
down by centrifuging at 4000 rpm for 3 min at 4°C. Media was removed and 1X PBS was 
added for washing the cells. Cells were resuspended in appropriate amount of lysis 
buffer; depending on the pellet size, for a 6-well plate, 100-120 µl while for a 12-well plate, 
50-60 µl of lysis buffer was used. Cells were briefly vortexed and kept on shaking at 4°C 
for 20 min for efficient lysis of the cells. Cell lysate was then centrifuged at 13,000 rpm for 
10min to let DNA settle down. 
Bicinchoninic acid assay (BCA assay) kit was used to normalize the concentration of 
proteins. In this assay, total concentration of protein is exhibited by a color change of 
sample solution from green to purple in proportion to protein concentration, which can 




were mixed in the ratio A: B = 98: 2 and 5 µl of protein were added to this mixture, 
incubated at 37°C for half an hour. Using Nanodrop spectrophotometer, a standard curve 
was prepared with different dilutions of BSA (provided with the kit); concentration of 
proteins was then measured using this standard curve. To the normalized amount of 
protein, 6X Laemmli buffers was added to the final concentration of 1X and samples were 
boiled at 95°C to reduce the disulfide bonds and denature the proteins.  
IV.1.9 Separation of proteins by SDS-PAGE (Sodium dodecyl sulfate- 
Polyacrylamide Gel electrophoresis)    
The method of SDS-PAGE, a widely used method for separating proteins based on their 
electrophoretic mobility was refined, in the way it is used nowadays, by Ulrich K. Laemmli 
(Laemmli, 1970). During cell lysate preparation, samples were boiled in Laemmli buffer, 
consisting of SDS as one of its component. SDS is an anionic detergent which imparts an 
even distribution of negative charge per unit mass of most of the proteins, thereby 
resulting in a fractionation by approximate size during electrophoresis. Gels that were 
used for the separation consisted of two layers- lower percentage of 
acrylamide/bisacrylamide (5%) stacking gel layer with pH 6.8 and higher percentage of 
acrylamide/bisacrylamide (varies from 6% -12%; depending on the size of the proteins to 
be separated) resolving gel layer with pH 8.8. Stacking gel formed the upper layer having 
well pockets for loading the sample; it served the purpose of compressing the proteins in 
a thin layer before they enter to the lower layer of resolving gel. In resolving gel, actual 
separation of proteins according to their size took place. Components of the gels are 
summarized in the Table IV.1-4.  
Normalized protein samples were loaded onto the gel, along with a pre-stained protein 
marker in a separate well pocket to track the separation and determine the size of the 
proteins. Gels were run at a constant voltage of 80V to 120V until desired separation was 
achieved. 
Table IV.1-4 Components of stacking and resolving gels 
 Stacking gel Resolving gel 
Acrylamide/bisacrylamide 5% 6-12% 
1M Tris, pH 6.8 126 mM   - 
1.5M Tris, pH 8.8    - 375mM 
10% SDS 0.1% 0.1% 
10% APS 0.1% 0.1% 





IV.1.10 Western blotting 
The technique (also known as Protein Immunoblotting) allows detection of specific 
proteins in a cell lysate. The method was introduced by Towbin et. al. (1979) and is now a 
routine technique for protein analysis. The proteins separated by electrophoresis are 
transferred to a nitrocellulose or polyvinylidene difluoride (PVDF) membrane. Membrane 
is then incubated with an antibody (called as primary antibody) against the epitope of a 
specific protein, followed by addition of another antibody (called as secondary antibody) 
which can bind to the species-specific region of the primary antibody and is conjugated to 
an enzyme like Horseradish peroxidase. The enzyme can convert its substrate into a 
product that produces luminescence, the light output is directly proportional to the amount 
of protein and can be captured by using film, a CCD camera or a phosphorimager 
designed for chemiluminescent detection. 
Once proteins were separated by SDS-PAGE, a sandwich of gel and membrane was 
prepared for electroblotting of proteins from gel to membrane. Transfer was performed at 
constant voltage of 100 V for 120 min (for the transfer of big proteins, PVDF membrane 
was used and transfer was done at constant voltage of 40 V for 24 h). After transfer was 
finished, membrane was stained with Ponceau S to check whether transfer was uniform 
and proteins were equally loaded. For blocking the unspecific sites on the membrane, 
where antibodies can bind, blocking buffer was added to the membrane for 45 min. It was 
followed by overnight incubation with appropriate dilution of primary antibody at 4°C (for 
more details on dilution of primary antibodies, refer to Table III.9-1), washing of the 
primary antibody with washing buffer (PBST or TBST) and addition of secondary antibody 
(1:10,000 dilution; for both primary and secondary antibody blocking buffer was used for 
making dilutions) for 1 h at room temperature. Membrane was then once washed with 
blocking buffer, followed by washing buffer. For visualizing the amount of protein, suitable 
amount of substrate solution (Immobilon Western HRP Substrate Peroxide Solution) was 
applied and luminescence was detected using a Chemocam HR 16 3200 imager. For 
weak signals, the more sensitive substrate solution SuperSignal West Femto Maximum 
Sensitivity Substrate was used.  
IV.1.11 Immunoprecipitation 
Immunoprecipitation (also referred as IP) is the technique of precipitating a protein using 
antibody that specifically binds to that protein. This method can be used to isolate and 
concentrate a particular protein from a sample having thousands of different proteins. This 
approach can be used for- identifying activation status of protein, determine post-
translational modifications and to study protein-protein or protein-nucleic acid interactions. 




target protein in a sample (such as cell lysate), this immune complex is then captured, or 
precipitated, on a beaded support to which an antibody-binding protein is immobilized 
(such as Protein A or G), and other proteins not precipitated on the beads are washed 
away. Finally, the protein is eluted from the support using denaturing buffers and 
analyzed by western blotting. 
For endogenous Immunoprecipiation, cells were seeded in atleast a 10 cm petri dish. 
Protease inhibitors (complete (mini) inhibitor mix from Roche) and phosphatase inhibitors 
(Na fluoride, Na pyrophosphate) were added to IP-lysis buffer just before its use. IP 
consists of 5 defined steps: Equilibration of beads- 50µl per sample of 50/50 Protein G 
sepharose beads slurry was suspended in an eppendorf tube, washed 3 times with IP-
lysis buffer by spinning the beads at 4000 rpm for 2 min at 4°C and finally resuspended in 
50 µl of IP-lysis buffer. Beads were stored at 4°C for later use. Sample preparation- It was 
performed on ice. Media was removed and cells adhered to petri dish were washed with 5 
ml PBS, followed by addition of 1 ml pre-chilled IP-lysis buffer (In case, treatment of cells 
leads to lot of cell death, media was taken in a falcon tube, centrifuged so that cells settle 
down, cells washed with PBS and resuspended in IP-lysis buffer). Cell lysate in IP-lysis 
buffer was scraped off the plate and transferred to an Eppendorf tube; it was then 
homogenized by pushing 5 times with a 26G insulin syringe. Sonication of lysate was then 
performed in Sonication device Bioruptor (Diagenode, Liège, Belgium) at medium power 
for 10 min to destroy the DNA. After it, cell lysate was centrifuged at 13000 rpm at 4°C for 
15 min to get rid of cell debris and supernatant was transferred to a new eppendorf tube. 
Preclearing- Equilibrated beads were added to the lysate and incubated for 1 h at 4°C on 
a rotor followed by centrifugation at 3000 rpm at 4°C for 4 min. Supernatant was 
transferred into a new eppendorf, 50 µl of this lysate was saved as input. Antigen- 
antibody reaction- To the rest of the lysate, 2 µg of antibody was added and incubated 
overnight at 4°C on a rotor. Antibody -beads coupling- 30 µl of equilibrated beads were 
put in the lysates and incubated 1 h at 4°C on a rotor, which were centrifuged at 3000 rpm 
for 2 min at 4°C. Supernatant was discarded; pellet was washed 5 times with 800 µl IP-
lysis buffer by spinning at 3000 rpm for 2 min with final spin at 6000 rpm for 2 min. 
Supernatant was discarded carefully, 30µl of 6 X laemmli buffer was added to the pellet 
and boiled at 95°C for 5 min. Samples were then run on SDS-PAGE and immunoblotted. 
Immunoprecipitation was performed to concentrate ATR using ATR (N-19) antibody from 
Santa Cruz and then immunoblotted to check the levels of phospho- ATR (T1989), which 





Immunofluorescence is the technique that utilizes fluorescent- labeled antibodies to detect 
specific target antigens, and therefore allows visualization of distribution of target antigen 
through the sample. More than one protein can be visualized in a single experiment using 
fluorescent tags that emit light at different wavelengths. 
For Immunofluorescence microscopy, automated Pathway 855 (Becton Dickinson, 
Franklin Lakes, NJ, United States) was used which can read the fluorescence intensity in 
96-well plates (Becton Dickinson). While performing the assay, media was removed and 
cells were fixed using 3.7% paraformaldehyde for 20 min at room temperature. All the 
following steps were performed at room temperature. Cells were then washed twice with 
1X PBS, followed by permeabilization of cells with 0.5% triton-X in PBS for 15 min and 
blocking unspecific binding sites for 15 min using blocking solution (3% BSA in PBS). 
Afterwards, primary antibody diluted in blocking solution was added for 1 h, followed by 
three washes in PBS and incubation with secondary antibody (with Alexa Fluor tags) and 
Hoechst (for staining nucleus) diluted in blocking solution for 45 min in dark. Cells were 
then blocked once in blocking solution for 5 min, washed in PBS for 3 times and 
suspended in PBS. The plate was covered with aluminium foil to prevent photobleaching 
of the fluorophore. Fluorescence was visualized and imaged under microscope. 
This technique was used to measure the intensity of gammaH2AX (readout of DNA 
damage) within the nucleus upon combination of inhibition/removal of Wee1/ Chk1/ ATR 
with or without gemcitabine. Appropriate excitation wavelengths were used for taking the 
images. Once images were captured in automated BD pathway microscope, they were 
analyzed using BD Pathway software, wherein the region of interest (ROI) can be defined 
by Hoechst stain and software counts the ROIs and the average intensity of desired 
fluorophore within each ROI as well as the average intensity per well. These values can 
be used to plot the graph of either the median value or the average value of intensity 








IV.2 Flow cytometric techniques 
IV.2.1  Cell cycle analysis using Propidium Iodide 
The method of cell cycle analysis was first described by a Van Dilla MA et.al in 1969 
using Fuelgen staining, while the use of propidium iodide for cell cycle analysis was 
presented by Krishan A. (1975). Cell cycle analysis utilizes flow cytometry to distinguish 
different phases of the cell cycle. In this method, cells are permeabilized and treated with 
a fluorescent dye that stains DNA quantitatively (widely used dye is Propidium iodide). 
The fluorescence intensity of the stained cells at the emission wavelength of the dye 
correlates with the amount of DNA in the cells. As the cells progress in the cell cycle from 
G0/G1 phase to S phase, they replicate their DNA, this enables to determine the relative 
amount of cells in G0/G1 phase, S phase and G2/M phase because the fluorescence of 
cells in the G2/M phase will be twice as high as that of cells in G0/G1 phase. 
Cells were seeded in 6-well plate, after 18- 24 h, they were treated with Wee1 inhibitor in 
the presence or absence of gemcitabine for 24 h and harvested afterwards. Harvesting 
was done by trypsinization and all the cells, trypsinized and floating, were combined. All 
the steps afterwards were performed in cold condition. Cells were centrifuged at 1800 rpm 
for 7 min and supernatant was removed. The pellet was then resuspended in 500 µl of 1X 
PBS++ (PBS with additional salts) by pipetting, followed by drop wise addition of 500µl of 
absolute ethanol while vortexing and it was repeated twice so that final volume was 2ml. 
Cells were then kept on shaking for 1 min and stored at -20°C overnight or at least for an 
hour to allow fixation to occur. After fixation, cells were centrifuged at 2200 rpm for 10 
min, supernatant was removed and 1 ml of PBS++ was added for 10 min to allow cells to 
rehydrate.Cell suspension was transferred to 1.5 ml Eppendorf tubes. PBS++ was 
washed away and cells were resuspended in 300 µl of 0.5 mg/ml RNAse A (pre- 
inactivated for DNAses by incubating at 70° C for 10 min), incubated at 37°C for 30 min 
and depending on the density of cells more PBS was added to dilute the cells. Directly 
before measurement, 3µl of propidium iodide (also known as PI, final concentration: 30 
µg/ml) was added to each 100µl of cell suspension. Measurement was done in FACS 
machine Guava PCA-96 Base System (Millipore, Merck, Darmstadt, Germany) which 
detects the fluorescence intensity (corresponding to PI) from each cell and the guava 
software allows it to be plotted in graphical format. Percentage of cells in each phase of 
cell cycle was determined using the software ModFit (Verity Software House, Topsham, 




IV.2.2 Double thymidine block for cell synchronization 
Cell synchronization improves conditions by which an actual process under scrutiny can 
be studied and helps clarify the linkage of the process to a particular cell cycle phase 
transition. Treatment with excess thymidine causes the arrest of the cells at G1/S border 
owing to the inhibition of DNA synthesis due to feedback inhibition of nucleotide synthesis 
caused by an imbalance of the nucleotide pool. Second treatment with thymidine allows 
the cells arrested at the late S phase due to first treatment to be recovered and proceed 
to G2/M phase pertaining them to arrest at G1/S phase of the next cycle. Therefore, most 
of the cells are synchronized at G1/S border using double thymidine block. 
This method was used to first synchronize the cells at G1/S border and follow the effect of 
Wee1 inhibition with or without gemcitabine on cell cycle. Cells were seeded in 6- well 
plate, after 24 h, they were treated with 2 mM thymidine for 16 h, followed by 4 times 
wash off of thymidine using fresh media. Cells were allowed to recover from arrest and 
proceed in the cell cycle by incubating in fresh media for 8 h and then treating them again 
with 2 mM thymidine for another 16 h. A well was harvested as time 0 h sample (t= 0 h) 
while others were treated with either DMSO or Wee1 inhibitor in the presence or absence 
of gemcitabine and harvested at different time- points. After harvesting, cells were 
permeabilized as mentioned in the section I.3.1 and stained for mitosis marker, MPM-2/ 
phospho H3. The staining is discussed in the next section I.3.3. 
IV.2.3 Analysis of cells in mitosis or premature mitosis 
Percentage of cells in mitosis can be determined by staining for proteins which specifically 
show up or are modified during mitosis. Phosphorylated Histone 3 at Ser10 (referred as, 
phospho H3 or PHH3) is a recently described immunomarker specific for cells undergoing 
mitosis. Mitotic cells can also be stained using MPM-2 (Mitotic Protein Monoclonal #2) 
antibody, this antibody recognizes a phosphorylated epitope (phospho-[Ser/Thr]Pro) 
found in phospho-proteins such as MAP2, HSP70, cdc25, and DNA topoisomerase IIα, 
most of which are phosphorylated at the onset of mitosis. The number of phospho- 
proteins recognized by MPM-2 varies from species to species and with the cell type. 
Premature mitosis is the phenomena where cells having incompletely duplicated DNA 
enter into mitosis; it can subsequently lead to mitotic catastrophe or cell death. Cells 
which enter into premature mitosis can be identified by staining for mitosis marker using 
flow cytometry. Cell population that stains positive for mitotic marker and have 2N DNA 
content is recognized as premature mitotic cell population. 
The staining for mitosis was used to determine the percentage of cells undergoing 




Cells were seeded in 6- well plate and were either first synchronized with double-
thymidine block or directly treated with Wee1 inhibitor in the presence or absence of 
gemcitabine. Cells were harvested and fixed as mentioned in section I.3.1. After fixation, 
cells were centrifuged at 2400 rpm for 5 min and supernatant was removed. Cells were 
resuspended in 1 ml of wash solution (0.05% Triton-X in PBS) and cell suspension was 
transferred to 1.5 ml Eppendorf tube. Cells were pelleted down by centrifuging at 2500 
rpm for 5 min and resuspended in 70 µl staining solution (2% FCS, 0.2% Triton-X in PBS) 
along with appropriate dilution of either MPM-2 or phospho-H3 antibody. Cells were 
incubated on ice for 2 h, followed by 2 washes with washing solution and then 
resuspended in 70 µl of staining solution with Alexa Fluor-488 tagged secondary antibody 
(at 1:2000 dilution). Cells were incubated on ice in dark for 1 h, washed once with 
washing solution and PBS subsequently and resuspended in 300 µl of 0.5 mg/ml RNAse 
A solution, incubated for 30 min at 37°C and proceeded as described in section I.3.1. 
Samples were measured either in Guava machine (mentioned above) or FACScanto II 
(Becton Dickinson, Franklin Lakes, NJ, United States). Data from BD machine analyzed 
using the software FACSDiva (from BD) while that from Guava machine was analyzed 
using Guava software and percentage of cells stained positive for mitosis having 2N DNA 























Figure IV-I Flow cytometric analysis of cells in premature mitosis. 
 2D graph shows the distribution of cells according to the DNA content (X- axis) and the 






IV.3 Real Time Quantitative Polymerase Chain Reaction (or qPCR)    
qPCR is a molecular biology technique based on Polymerase Chain Reaction (PCR) 
which is used to amplify as well as quantify the target DNA molecule. This technique 
utilizes fluorescent dye or fluorescently- tagged oligonucleotide probe for detection of the 
amount of DNA. It is successfully been used for quantifying the gene expression or mRNA 
levels. 
Analysis of mRNA levels using qPCR requires following steps: 
• Isolation of total RNA  
• Conversion of mRNA to cDNA with Reverse transcriptase 
• Quantitation of cDNA using PCR 
 
IV.3.1 Isolation of total RNA 
Total RNA from human cells was isolated using guanidinium thiocyanate-phenol-
chloroform extraction method. In a 6-well plate, cells were washed with 1ml of PBS, 
trypsinized and 500µl of DMEM was added. Cells were resuspended, transferred to an 
Eppendorf tube and kept on ice, followed by centrifugation at 2000 rpm for 10 min a 4°C. 
Media was removed, cells were resuspended in 1ml of Trizol reagent (monophasic 
solution of phenol and guanidinium thiocyanate) and incubated for 5 min to lyse cells, 
dissolve nucleoprotein complexes and dentaure protein. For the separation of RNA, 200 
µL of chloroform was added and the samples were shaken vigorously for few seconds. 
After 3 min incubation at RT, phases were separated by centrifuging at 12,000 g for 15 
min at 4°C. RNA from the upper aqueous phase was then purified by precipitation with 
500 µL of isopropanol. Samples were shaken, incubated overnight at -20°C and 
centrifuged at 12,000 g for 10 min at 4°C. The pellet was washed with 75% ethanol. To 
remove any residual protein contamination, the RNA was resuspended in 50µl water and 
once more precipitated in the presence of 300 mM sodium acetate, 1.25 times ethanol 
and 1µl of glycogen blue at -80°C for 1h. The pelleted RNA was washed with 70% 
ethanol, air-dried, resuspended in 22µl H2O and stored at -80°C. 
IV.3.2 Conversion of mRNA to cDNA with Reverse transcriptase 
Isolated RNA was reverse transcribed with the viral M-MuLV reverse transcriptase and 
the use of a mixture of anchored oligo-dT primers and random nonamers. The oligo-dT 
primers hybridize to the poly (A) tail of mRNAs while random nonamers ensure reverse 




For each reverse transcriptase (RT) reaction, 1 µg of RNA was used and incubated with 2 
µL of 100 µM combined primers and 4 µL of dNTPs (2.5 mM each) in a total volume of 16 
µL for 5 min at 70°C to resolve secondary RNA structures. Then, the RT reaction mix was 
prepared as detailed in  
Table IV.3-1 Reagents required for Reverse Transcription reactionand added to the 
sample. For each sample, a second RT reaction mix was prepared without reverse 
transcriptase to control for DNA contamination. For reverse transcription, the samples 
were incubated at 42°C for 1 h, then heated to 95°C for 5 min to inactivate the enzyme 
and 20-30 µL water was added.  
Table IV.3-1 Reagents required for Reverse Transcription reaction 
Reagent Volume (µl) 
10X RT Buffer 2 
RNase Inhibitor 0.25 
Reverse transcriptase 0.125 
Water 1.625 
 
IV.3.3 Quantitation of cDNA using PCR 
With qPCR, the amplification of a specific DNA sequence can be monitored in real time. A 
fluorescent dye, such as SyBr Green, that intercalates into double-stranded DNA is used 
to measure the product quantity after every replication cycle. The product of gene of 
interest in a sample is normalized to that of a reference gene (usually any gene whose 
expression level is considered to be stable under the treatment conditions), and then the 
relative abundance of the product of gene of interest in treated sample as compared to 
untreated sample is calculated. To specifically amplify the cDNA of an mRNA of interest, 
sequence-specific primers are designed in a way that a short fragment (usually 50 to 300 
bp) of the cDNA template is amplified and that they either span exon-junctions or are 
located in different exons. Thus, amplification of intron-containing genomic DNA can be 
excluded.  
For the quantification of Wee1 and ATR mRNA, cDNA template levels were normalized to 
either GAPDH/36B4 mRNA. cDNA resulting from RT reactions without reverse 
transcriptase and qPCR samples without cDNA template served as controls. All samples 
were analyzed in triplicates. The qPCR reaction mix and the qPCR cycler program are 




Table IV.3-2 Reaction mix for qPCR 
Reagent Volume (µl) 
25X qPCR reaction mix 14 
Forward primer (10 pmol/µl) 0.75 




Table IV.3-3 Cycler program for qPCR 
Temperature Time  
95°C 2 min  
95°C 15 sec  
40x 60°C 1 min - read 
Melting curve  
 
The fluorescence of each sample was measured once per cycle at the end of elongation 
(“read”). Purity of the qPCR product was controlled with a melting curve that should yield 
a single melting point for a specific product.  
The resulting Ct values (amplification cycle at which the fluorescence reaches the 
determined threshold) were used for the calculation of the relative amount of template 
using the ΔΔCt method, assuming 100% amplification efficiency (i.e. a product doubling 
with each cycle):  
Relative mRNA expression =〖 2〗^ ((ΔCt ref. gene treated/target gene treated)-(ΔCt 
ref. gene untreated/target gene untreated)) 
 
IV.4 Statistical analysis 
Statistical calculations were performed with Microsoft Excel. Statistical significance was 
determined using the unpaired, two-tailed student’s t-test. Significance was assumed for 
p-values below 0.05. Asterisks in figures indicate resulting p-values as follows: * p < 0.05, 
** p < 0.01, *** p < 0.001. n.s. = not significant. n in figure legends indicates the number of 






V.1 Chk1, Wee1 and ATR inhibition cooperate with gemcitabine 
V.1.1 Chk1, Wee1 or ATR inhibition in combination with gemcitabine intensifies 
DNA damage response 
We quantified the phosphorylation of H2AX, referred to as γH2AX, upon combining the 
inhibition of checkpoint kinases, namely Chk1, Wee1 and ATR, with gemcitabine in 
different human pancreatic tumor cell lines. Cell lines used were- Panc1, MiaPaCa2, 
BxPC3, these cell lines have a mutated form of p53 (Deer et al. 2010, Schumacher et al. 
1999). Along with these cell lines, we used U2OS, a human osteosarcoma cell line having 
wild-type p53. 
We used pharmacological inhibitors against Chk1, Wee1 and ATR (SB218078, MK-1775, 
and VE-821 respectively) to block their activity. VE-821 is the selective and potent 
inhibitor of ATR (Reaper et al. 2011). SB218078 is a cell permeable, ATP-competitive,  
potent and selective inhibitor of checkpoint kinase (Chk1) in vitro (Jackson et al. 2000). 
MK-1775 selectively and potently inhibits Wee1 both in vitro and in vivo (Hirai et al. 2009). 
The efficiency of these inhibitors was confirmed through immunoblot staining of their 
respective substrates (Refer to Figure VIII-I in appendix). 
Cells were treated with the inhibitors and gemcitabine for 24 h and afterwards analyzed 
for γH2AX intensity by quantitative immunofluorescence. We found that the inhibition of 
each of the three kinases cooperated with gemcitabine in potentiating the DNA damage 
response as evidenced by increased average γH2AX intensity (Figure V-I). Inhibition of 
Wee1 alone also induces DNA damage response. This observation was made in all of the 
above-mentioned pancreatic tumor cell lines as well as osteosarcoma cell line. However, 
in MiaPaCa2 cells, ATR and Wee1 inhibition led to a lot of cell death resulting in loss of 
cells. This could be a reason for a minor increase in γH2AX intensity with these two 
inhibitors when combined with gemcitabine. Earlier studies performed using these 
inhibitors have shown sensitization of tumor cells (Prevo et al. 2012), Rajeshkumar et al. 
2011, Azorsa et al. 2009); however, our study focused on comparing the extent of DNA 
damage response upon combination of inhibition of these kinases with gemcitabine.  
We also investigated the DNA damage response after transiently removing the checkpoint 
kinases with small interfering RNAs (siRNAs). Knockdown efficiency of siRNAs was 




Figure VIII-III in appendix). Cells were treated with the respective siRNAs for 48 h, 
followed by 24 h of gemcitabine. They were fixed and analyzed for γH2AX intensity by 
immunofluorescence. We found increased gemcitabine-triggered γH2AX accumulation 
upon Wee1 or ATR knockdown in U2OS cells and BxPC3 cells, but not with Chk1 
knockdown. In Panc1 cells, a similar cooperation with Chk1 and Wee1 knockdown but not 
ATR knockdown was observed, while MiaPaCa2 cells were sensitized by all three 
knockdowns (Figure V-II).  
            
         
Figure V-I Three checkpoint inhibitors cooperate with gemcitabine.  
Cells were treated for 24 h with 300nM gemcitabine, followed by addition of 5µM SB 218078; 1µM 
(Panc1) or 0.5µM (U2OS) MK-1775; 10µM VE-821 (referred to as Chk1i, Wee1i and ATRi 
respectively, for their target kinases) in the presence of 300nM gemcitabine (Gem) for 20 h. Cells 
were then fixed and stained for γH2AX. Measurement and analysis was done using automated 
immunofluorescence microscopy (BD Pathway). Error bars represent the SD, n=3. 
 
These results show that the sensitization of cells by knockdown of the checkpoint kinases, 
in combination with gemcitabine, is dependent on cell type. This might be due to presence 
of different isoforms of the protein in different cell line or the knockdown induces cell 




case with Chk1 knockdown in U2OS and BxPC3 cells). Wee1 knockdown with one of the 
siRNAs shows more γH2AX intensity since this siRNA was more efficient in removing the 










Figure V-II Depletion of the checkpoint kinases sensitize cells towards gemcitabine. 
Cells were transfected with 10nM siRNAs for 48 h, followed by 24 h of 300nM gemcitabine; they 
were fixed and analyzed for γH2AX intensity by immunofluorescence. Error bars represent the SD, 
n=3. C1 and C2 are negative control #1 and #2 siRNAs respectively. Left panel labeled as ´No 
gem´ represent cells not treated with gemcitabine. 
 
V.1.2 Cell growth retards upon combination of Chk1, Wee1 or ATR inhibition with 
gemcitabine  
The combination of the above-mentioned inhibitors with gemcitabine increased the DNA 
damage response after 24 h; however, we were interested to investigate the long-term 
effect of the combination treatment by following the growth of the cells over a period of 
time. Cells were treated with the drugs in the presence or absence of gemcitabine for 24 h 




(depending on the survival of the cells). The results imply that combining Wee1 or ATR 
inhibitor with gemcitabine retards the growth of the cells (irrespective of the cell line) to a 
much higher extent than Chk1 inhibitor in Panc1 and MiaPaCa2 cells. In Panc1 cells, 
Chk1 inhibition even promotes the cell growth to some extent. In U2OS cells, all the 




Figure V-III Long-term survivability of cells decreases upon combination of Wee1 or ATR 
inhibitor with gemcitabine.  
Cells were treated with 2.5µM Chki, 0.5µM Wee1i and 5µM ATRi in the absence (Control) or 
presence of gemcitabine (Gem) at the concentrations indicated in the figure. After 24 h, all drugs 
were removed and fresh medium was added. Cells were incubated for 8-13 days and confluency 
was measured each day using brightfield microscopy (Celigo cell cytometer). Error bars represent 




From the above experiments, we deduce that the Wee1 inhibitor has a high potency to 
sensitize pancreatic tumor cells. 
V.2 Wee1 inhibition inactivates the ATR-Chk1 pathway 
V.2.1 Inhibition or removal of Wee1 in the context of gemcitabine treatment leads 
to a decrease in Chk1 activation 
To analyze the signaling pathways involved in the DNA damage response upon Wee1 
inhibition, we detected DNA damage signaling intermediates, apart from γH2AX, through 
immunoblotting. Cells were treated with inhibitor in the presence or absence of 
gemcitabine for 24 h and cell lysates were analyzed for the activation of DNA damage 
response proteins. The activity of the inhibitor was verified by staining for phosphorylation 
of Cdk1 at Tyr15 (Parker and Piwnica-Worms 1992); as expected this phosphorylation 
was decreased upon treatment with Wee1 inhibitor (Figure V-IV(a)). Phosphorylation of 
Chk1 at Ser317 is mediated by ATR which activates Chk1 (Hui Zhao and Piwnica-Worms 
2001). It was observed that Chk1 phosphorylation (Ser317) decreased upon combination 
of Wee1 inhibitor with gemcitabine. Total levels of Chk1 in U2OS cells were slightly 
decreased which might be due to p53 activation in response to DNA damage that down-
regulates Chk1 expression (Gottifredi et al. 2001). Regulation of Wee1 by Chk1 has been 
studied, and Chk1 phosphorylates Wee1 to inhibit Cdc2 phosphorylation at Tyr15 
(O’Connell et al. 1997). However, there is no previous report showing that Wee1 controls 
Chk1 phosphorylation or its activation. Gemcitabine is a nucleoside analog that causes 
replicative stress leading to activation of ATR. Chk1 is phosphorylated and activated by 
ATR in response to DNA damage; we speculated that the ATR-Chk1 pathway might be 
compromised upon combination of Wee1 inhibition with gemcitabine. In contrast, the 
γH2AX intensity did not decrease. We speculated that ATM or DNA-PK might be 
responsible for maintaining the levels of γH2AX.  
Besides Wee1 inhibition, we also performed transient knockdown of Wee1 and observed 
a reduction in phosphorylation of Chk1 when combined with gemcitabine in both U2OS 
and Panc1 cells. The relative decrease in phospho-Chk1 as compared to total Chk1 
protein was more upon Wee1 knockdown than control (Figure V-IV(b)). 
We performed quantitative immunofluorescence analysis to check the phosphorylation of 
Rad17 at Ser645, another ATR substrate, upon combining the inhibition of checkpoint 
kinases with gemcitabine. Cells were treated with the 1µM Wee1 inhibitor and 
gemcitabine for 24 h and afterwards analyzed for phospho-Rad17 intensity. We found that 













Figure V-IV Wee1 inhibition or knockdown in combination with gemcitabine, reduces Chk1 
activation.  
U2OS and Panc1 cells were treated with 1µM Wee1 inhibitor -MK1775 (referred to as Wee1i) 
and 300nM gemcitabine (Gem), after 24h cells were harvested and cell lysate was 
immunoblotted. The substrate of ATR, Chk1 was analyzed for its phosphorylation. tChk1, 
tCdk1 stands for the total proteins while pChk1, pCdk1 for phosphorylated forms. (b) Cells 
were made deficient of Wee1 by transfecting with siRNA (Wee1 #1) for 48h, followed by 
gemcitabine treatment for 24h and proceeded as in (a). Cells transfected with siRNA 
negative control #1 were used as control (Cntrl). Relative density represents the ratio of 
protein intensities in Wee1 knockdown to control. (c) Cells were treated as mentioned in (a), 
after 24h cells were fixed and analyzed by automated immunofluorescence microscopy. 






We conclude that inhibition of Wee1 in the presence of gemcitabine hampers the ATR- 
Chk1 signaling pathway and leads to inactivation of Chk1 and Rad17. 
V.2.2 ATR activation is hampered when Wee1 inhibition is combined with 
gemcitabine 
To address whether Wee1 inhibition, when combined with gemcitabine, leads to the 
inactivation of ATR, we detected ATR phosphorylation at Thr1989; phosphorylation of this 
site has earlier been described as a marker of ATR activity (Nam et al. 2011). ATR was 
immunoprecipitated to concentrate the protein and then immunoblotted to detect 
phospho-ATR (Thr1989). Phospho-ATR levels, as expected, were increased upon 
gemcitabine treatment, but when gemcitabine was combined with Wee1 inhibitor, the 
levels of this protein were decreased (Figure V-V), suggesting impaired activity of ATR. 
This decreased activation of ATR was independent of the p53 status of the cells, as both 
U2OS and Panc1 cells showed reduction of phospho-ATR upon Wee1 inhibition. 
These results suggest that Wee1 governs the activation of the ATR-Chk1 pathway upon 





Figure V-V ATR activity decreases upon combination of Wee1 inhibitor and gemcitabine.  
Cells were treated with 1µM Wee1 inhibitor (MK1775) and 300nM gemcitabine for 24h. Cells 
were harvested and cell lysate was prepared, ATR was immunoprecipitated and 
immunoblotted for phospho-ATR (Thr1989). 
 
V.3 Time-dependent reduction of Chk1 phosphorylation occurs 
in combination treatment 
To investigate whether Wee1 inhibition is directly affecting the activation of ATR-Chk1 
signaling, we performed a time-course study. We treated the cells with Wee1 inhibitor in 
the presence of gemcitabine and harvested them at different time-points after treatment. 




24 h of treatment, the decrease in phospho-Chk1 levels was even stronger. After 8 h of 
treatment, we observed an increase in γH2AX as well as phospho-Chk1 levels due to 
increased DNA damage response upon combination treatment. However, only after long 
exposure to the treatment, phosphorylation of Chk1 decreases, suggesting indirect 
regulation of Wee1 in maintaining Chk1 phosphorylation (Figure V-VI). 
 
 
Figure V-VI Chk1 activity reduces in a time-dependent manner upon combining Wee1 
inhibition with gemcitabine.  
Cells were treated with 1µM Wee1 inhibitor (MK1775) and 300nM gemcitabine. Cells were 
harvested at different time-points and cell lysate was immunoblotted. tChk1 stands for the total 






V.4 Apoptosis is not the cause of ATR inactivation upon Wee1 
inhibition 
We observed an increase in PARP cleavage when Wee1 inhibition was combined with 
gemcitabine, indicating apoptosis in these cells (Figure V-IV(a)). As apoptosis could lead 
to dephosphorylation of proteins (Baxter and Lavin 1992) and moreover, PP2A, a 
phosphatase which can regulate Chk1 dephosphorylation (Leung-Pineda, Ryan, and 
Piwnica-Worms 2006) is up-regulated during apoptosis (Santoro et al. 1998), we 
addressed the question whether apoptosis might be a cause for decreased activation of 
ATR pathway. Therefore, we treated U2OS and Panc1 cells with gemcitabine and/or 
Wee1 inhibitor in the presence of Z-VAD.fmk, a pan caspase inhibitor that irreversibly 
binds to catalytic sites of caspase proteases and can inhibit apoptosis (Garcia-Calvo et al. 
1998). Analysis of the blots shows that reduction in Chk1 phosphorylation occurs 
independently of caspase activation (Figure V-VII). 
 
V.5 Mitotic catastrophe does not lead to down-regulation of ATR-
Chk1 pathway 
It is known that Wee1 inhibition in S-phase arrested cells leads to premature mitosis and 
consequently to mitotic catastrophe (Aarts et al. 2012). As many kinases undergo 
modulation in their activity while entering into mitosis, our proposition was that ATR 





Figure V-VII Caspase activity does not cause loss of Chk1 activation. 
Cells were treated with 1µM MK1775 (Wee1i) and 300nM gemcitabine (Gem) in the presence 
or absence of 20µM caspase inhibitor, Z-VAD.fmk (Z-VAD). After 24h, the cells were 
harvested and western blot analysis was done. tChk1, tCdk1 stands for the total proteins 





To address this, we performed western blot analysis in MCF7, a breast cancer cell line. 
This cell line (with wild-type p53) has been reported to be resistant (to a significant extent) 
to premature mitosis upon Wee1 inhibition in the presence of gemcitabine than other 
breast tumor cell lines with mutant p53 (Aarts et al. 2012). We first verified this finding 
through phospho-H3 staining in flow cytometry. We detected the percentage of cells that 
stained positive for phospho-H3 with <4N DNA content. This percentage of cells 
corresponds to the fraction entering into mitosis prematurely. It was found that the amount 
of cells entering into premature mitosis was indeed significantly less in MCF7 cells as 
compared to U2OS cells upon combination of Wee1 inhibition with gemcitabine (Figure 
V-VIII(a)). Afterwards, MCF7 cells were treated with Wee1 inhibitor in the 
presence/absence of gemcitabine for 24h for western blot analysis. We found decreased 
phosphorylation of Chk1 as well as ATR even in these cells upon Wee1 inhibition with 
gemcitabine (Figure V-VIII(b,c)). Furthermore, we investigated whether caspase activity 
affects ATR-Chk1 pathway in MCF7 cells. For the same, we performed western blotting 
with combination treatment in the presence of Z-VAD.fmk and could not rescue 
inactivation of Chk1 (Figure V-VIII(b)). 
From here, we infer that premature mitosis or mitotic catastrophe is not necessary for the 
















Figure V-VIII Mitotic catastrophe does not lead to reduction in ATR-Chk1 activity.  
(a) U2OS and MCF7 cells were treated with 1µM Wee1 inhibitor/DMSO in the presence or 
absence of 300nM gemcitabine for 24h. Cells were harvested, stained with PI and phospho-H3. It 
was followed by flow cytometric analysis. (b) MCF7 cells were treated as mentioned in (a) either in 
the presence or absence of Z-VAD.fmk and cell lysate was immunoblotted. tChk1 stands for the 
total protein while pChk1 for phosphorylated forms. * represents unspecific band. (c) MCF7 cells 
were treated as in (a) and then cells were harvested and cell lysate was prepared, ATR was 
immunoprecipitated and immunoblotted for phospho-ATR (Thr1989). 
 
 
V.6 Decreased activation of ATR-Chk1 pathway is mediated 
through Cyclin-dependent kinases  
V.6.1 Inhibition of Cyclin-dependent kinases (Cdks) using roscovitine restores 
Chk1 phosphorylation 
Wee1 is a checkpoint regulator that has a major role in controlling the transition of cells 




Cdk1 and Cdk2 at the conserved Tyr15 residue (Guertin et al. 2012). Thus, Wee1 
inhibition can lead to Cdk1/2 activation. To test whether the inhibition of the ATR-Chk1 
pathway by Wee1 inhibition is due to Cdk activation, we performed inhibition of Cdks 
using roscovitine along with Wee1 inhibition and gemcitabine. Roscovitine is a potent, 
reversible and selective inhibitor of Cdks and binds competitively to the ATP-binding 
domain of these kinases (Meijer et al. 1997). Western blot analysis showed rescue of 
Chk1 and ATR phosphorylation when Cdks were inhibited (Figure V-IX(a, b)).  
These findings imply that inactivation of the ATR-Chk1 pathway is mediated through Cdks 
upon Wee1 inhibition.  





Figure V-IX Cdk inhibition rescues decreased Chk1 and ATR activity upon Wee1 inhibition 
with gemcitabine. 
(a) A potent and selective inhibitor of Cdks, roscovitine, restores Chk1 phosphorylation. Panc1 and 
U2OS cells were treated with 20µM roscovitine in the presence or absence of Wee1i and Gem, 
after 24h cells were harvested and western blot analysis was performed. (b) Cells were treated as 






V.6.2 Inhibition of Cdk1 could recover Chk1 phosphorylation 
We also used a selective inhibitor of Cdk1, RO-3306. This inhibitor is an ATP-competitive 
inhibitor of Cdk1 and has nearly 10-fold selectivity relative to Cdk2 (Vassilev et al. 2006). 
We found that this inhibitor, when combined with Wee1 inhibition and gemcitabine, could 
restore the phosphorylation of Chk1 (Figure V-X). In conclusion, Cdk1 plays an active role 
in inactivating ATR-Chk1 pathway. 
However, there are no studies showing direct involvement of Cdk in ATR inactivation. 
Therefore, we tested some of the known substrates of Cdk which could potentially 
mediate ATR pathway inactivation. 
 
             
Figure V-X Cdk1 inhibition recovers Chk1 and Rad17 phosphorylation upon Wee1 inhibition 
and gemcitabine treatment.  
Panc1 and U2OS cells were treated with 10µM RO-3306 (Cdk1 inhibitor) in the presence or 




V.7 Cdk substrates Mus81 and Retinoblastoma protein do not 
mediate down-regulation of ATR pathway  
V.7.1 Mus81 does not govern inactivation of ATR signaling pathway 
Mus81 is a structure-specific endonuclease involved in cleaving branched DNA (Osman 
and Whitby 2007). It forms a heterodimeric complex with Eme1 (another endonuclease) 
which is found to be controlled by Wee1 directly or through Cdk (Domínguez-Kelly et al. 
2011). Wee1 inhibition hyperactivates Cdk, which then leads to deregulation of DNA 




Mus81/Eme1 (Martín, Domínguez-Kelly, and Freire 2011). Upon inhibition of Wee1, 
Mus81 processes DNA breaks and ensures recovery from replication stress (Hanada et 
al. 2007, Murfuni et al. 2013). We hypothesized that Mus81 might be regulating the ATR 
pathway so that cells could move on in the cell cycle once DNA breaks are processed. To 
test this, we depleted the cells of Mus81 and Wee1 and treated them with gemcitabine for 
24 h. Western blotting analysis revealed that co-depletion of Wee1 and Mus81 could not 
rescue decreased phosphorylation of Chk1 and Rad17, compared to Wee1 single 
knockdown. However, we found that knockdown of Mus81, in combination with 
gemcitabine, leads to decreased γH2AX and Chk1 phosphorylation (Figure V-XI). We do 
not fully understand this phenomenon but speculate that processing of stalled replication 
forks by Mus81-Eme1 complex might lead to the generation of a DNA damage response. 
In line with our speculation, Domínguez-Kelly and colleagues observed a diminished DNA 
damage response, generated by Wee1 removal, upon co-depletion of Mus81 
(Domínguez-Kelly et al. 2011). 
Thus, these results illustrate that Mus81 does not lead to inactivation of the ATR pathway 
upon inhibition of Wee1 in the presence of gemcitabine. Instead, Mus81 maintains Chk1 








Figure V-XI Mus81 does not mediate ATR-Chk1 inactivation upon Wee1 inhibition and 
gemcitabine treatment. 
(a) Cells were made deficient of Wee1 and/or Mus81 by transfecting with siRNAs (Wee1#1, 
Mus81) for 48h, followed by gemcitabine treatment for 24h. Cells were harvested and western blot 
analysis was performed. Negative Control No.1 siRNA transfected cells were used as control 
(Control). (b) Panc1 cells were transfected with negative control no.1 and Mus81 #1 siRNA. After 
48h, cells were harvested and protein lysate was immunostained.  
 
 
V.7.2 The Retinoblastoma protein, negatively regulated by Cdks, does not affect 
the ATR pathway 
Functional inactivation of the Retinoblastoma protein (also referred to as pRb) has been 
found to be controlled by three distinct Cyclin-Cdk complexes, namely CyclinD-Cdk4/6, 
CyclinE-Cdk2 and CyclinA-Cdk2/1 (Lundberg and Weinberg 1998). As Cdks could 
negatively regulate pRb, we hypothesized that pRb might be involved in maintaining the 
activation of ATR signaling pathway. pRb, being a repressor of the E2F transcription 
factor family could regulate ATR, e.g. through E2F-mediated transcription. 
To assess whether there is a change in the levels of ATR mRNA, we performed 
quantitative RT-PCR for ATR in Panc1 cells where Wee1 was knocked down in the 
presence of gemcitabine. It was found that the mRNA levels of ATR did not significantly 
change upon knockdown of Wee1 (Figure V-XII(a)). This observation argues against the 
control of ATR at the level of transcription.  
To test whether pRb itself could affect the activation of ATR, we used Hela cells that 
contain inactive pRb due to expression of the E7 protein from papilloma virus, which can 
bind and inactivate pRb (Gonzalez et al. 2001). We treated this cell line with Cdk1 
inhibitor in the presence of Wee1 inhibitor and gemcitabine and analyzed the proteins 
through western blotting. We observed that even in Hela cells, Cdk inhibition could rescue 
the phosphorylation of Chk1 as well as Rad17 (Figure V-XII(b)). This experiment shows 
that the Retinoblastoma protein does not sustain the ATR pathway and that Wee1 








                  
Figure V-XII Retinoblastoma protein does not mediate the down-regulation of ATR-Chk1 
activity upon inhibition of Wee1 and gemcitabine treatment.  
(a) Panc1 cells were transfected with 10nM siRNA against negative control no. 1 (control) or 
Wee1#1 (Wee1). After 48 h, cells were treated with gemcitabine for 24 h. Cells were harvested, 
RNA was isolated and quantitative RT-PCR was performed. 36B4 mRNA was used as a reference 
gene for normalization. Error bars represent standard error of the mean. CFX manager software 
was used for the calculations. (b) HeLa cells were treated with Wee1i, gemcitabine and/or 






V.8 Polo- like kinase 1 (Plk1) impedes the ATR- Chk1 pathway   
V.8.1 Inhibition of Plk1 recovers decreased Chk1 and Rad17 activation upon Wee1 
inhibition and gemcitabine  
It has been shown that the yeast homolog of Plk1, cdc5, is activated by the Cdk1, 
homolog cdc28 in yeast (Mortensen et al. 2005) (Simpson-Lavy and Brandeis 2011). Plk1 
is also known to down-regulate the ATR-Chk1 pathway by acting at different levels of this 
signaling pathway. It phosphorylates the adaptor protein Claspin and marks it for 
degradation by the ubiquitin ligase SCFβ-TrCP1/2, thereby restraining Chk1 activation 
and regulating the recovery from the DNA replication checkpoint response (Niels Mailand 
et al. 2006), (Peschiaroli et al. 2006). Another level of regulation of ATR-Chk1 signaling 
pathway by Plk1 is through Sae2 in yeast, the functional ortholog of human CtIP 
(Donnianni et al. 2010); CtIP is involved in DNA resection and is required to sustain 
checkpoint signaling (Kousholt et al. 2012). To investigate the role of Plk1 in the negative 
regulation of ATR-Chk1 activity, we incubated cells with a Plk1 inhibitor, in the presence 
of the Wee1 inhibitor and gemcitabine. Through immunoblot analysis, it was found that 
the inhibition of Plk1 could recover the decreased phosphorylation of Chk1. Hence, Plk1 
activity is required for the attenuation of ATR-Chk1 signaling upon Wee1 inhibition (Figure 
V-XIII(a)).  
Plk1 has a phospho-peptide binding domain that binds to the proteins ‘primed’ or 
phosphorylated by kinases, thereby facilitating localization of Plk1. Kinases known to 
prime Plk1 substrates include Cdk1, that drives the cells into mitosis (K. S. Lee et al. 
2008). Plk1 activity is also regulated by Aurora A kinase through an auxiliary protein, Bora 
(Seki et al. 2008). Binding of Bora to Plk1 facilitates the phosphorylation of Plk1 at Thr210 
by Aurora A causing the activation of Plk1. To validate the activation of Plk1 upon Wee1 
inhibition and its inactivation upon Plk1 and Cdks inhibition, we performed western blot 
analysis after treatment with these inhibitors. We found that the levels of phosphorylated 
Plk1 (Thr210) increased with Wee1 inhibition and that this phosphorylation is decreased 
when Plk1 and Cdk inhibitors were added (Figure V-XIII(b)). Therefore, we conclude that 
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Figure V-XIII Inhibition of Plk1 rescues ATR-Chk1 activity.  
(a) Panc1 and U2OS cells were treated with Wee1i or DMSO with or without gemcitabine in the 
presence or absence of Plk1 inhibitor, GSK 461364 (referred to as Plk1i) at the concentrations 
indicated in figure for 24 h. Cells were harvested and cell lysate was immunoblotted. Blots were 
stained for phosphorylation of ATR substrates- Chk1 and Rad17. HSC 70 or β-Actin was stained 
as loading control. (b) Panc1 and U2OS cells were treated with Wee1i, Plk1i and combination of 
Wee1i with Plk1i or Roscovitine in the presence of gemcitabine at the indicated concentrations for 
8 h. Cells were harvested and cell lysate was immunoblotted. Blots were stained for 
phosphorylation of Plk1 (Thr210). β-Actin was stained as loading control. DMSO treated cells were 
used as negative control. 
Immunoblot in (a) for Panc1 cells was conducted by Indira Memet. 
 
V.8.2 Plk1 mediates inactivation of Chk1 through Claspin degradation 
Claspin is an adaptor protein which binds to Chk1 and facilitates its activation by ATR 
(Chini and Chen 2003). To determine whether Chk1 inactivation by Plk1 is mediated 
through Claspin, we checked the levels of Claspin upon Wee1 inhibition as well as Plk1 
and Cdks inhibition. Through immunoblotting, we showed that Claspin level was 
decreased upon Wee1 inhibition with gemcitabine and that it was restored when Plk1 or 
Cdks inhibitor is combined (Figure V-XIV(a)). We could also show by western blotting that 
removal of Claspin reduces Chk1 phosphorylation (Figure V-XIV(b,c)). From here, we 
























             
Figure V-XIV Plk1 causes Claspin degradation which leads to Chk1 inactivation upon Wee1 
inhibition with gemcitabine.  
(a) Panc1 and U2OS cells were treated with Wee1i, Plk1i and combination of Wee1i with Plk1i or 
Roscovitine in the presence of gemcitabine at the indicated concentrations for 8 h. Cells were 
harvested and cell lysate was immunoblotted. Blots were stained for total levels of Claspin. HSC 
70 was stained as loading control. DMSO treated cells were used as negative control. (b) Claspin 
was knocked down in the cells by transfecting with 10nM siRNAs for 48 h, followed by treatment 
with 300nM gemcitabine. Cells were harvested at different time points after gemcitabine addition 
i.e., 0 h, 6 h, 10 h and 12 h. Cell lysate was immunoblotted and stained for Chk1 and Rad17 
phosphorylation. β-Actin was used as loading control. (c) Immunoblot showing the Claspin 











Clinical relevance of combination therapy 
V.9 Nutlin-3 pretreatment attenuates DNA damage response and 
apoptosis upon Wee1 inhibition with gemcitabine in p53- 
proficient cells 
V.9.1 U2OS, a cell line with wild-type p53, resists cytotoxic effects of combination 
treatment upon nutlin-3 pretreatment 
Nutlin-3 is an inhibitor of Mdm2-p53 interaction, thereby, causing non-genotoxic 
accumulation of p53 which results in cell cycle arrest and/or apoptotic response (Miyachi 
et al. 2009). In a previous study in our lab, it has been shown that the pretreatment of 
U2OS cells with nutlin-3 followed by transient exposure to nutlin-3 and gemcitabine 
reduces gemcitabine related- cytotoxicity in these cells (Kranz and Dobbelstein 2006). We 
tested whether treatment of U2OS cells with nutlin-3 prior to combination therapy, Wee1 
inhibitor and gemcitabine, could decrease the cytotoxic effects of the latter treatment. To 
address this, we treated the cells with sub-lethal dose of nutlin-3 for 24h, followed by 
addition of nutlin-3 with Wee1 inhibitor in the presence of gemcitabine for another 24h. 
Western blot analysis showed that γH2AX levels decrease upon nutlin pre-treatment, 
apart from it, cleaved PARP, cleaved caspase-3 and phosho-H3 levels also decreases as 
compared to nutlin untreated cells. Also, p53 was stabilized and there was induction of 
p21 with nutlin treatment reflecting the activity of nutlin (Figure V-XV). From here, we 
deduce that treatment of U2OS cells with nutlin prior to combination therapy reduces DNA 
damage response, apoptosis as well as the number of cells entering into mitosis caused 




    
Figure V-XV Nutlin-3 attenuates the cytotoxicity caused by combination of Wee1 inhibitor 
and gemcitabine.  
U2OS cells were treated with 8µM nutlin-3 for 24 h, followed by treatment with 1µM Wee1 inhibitor, 
300nM gemcitabine and 8µM nutlin-3 for another 24 h. Cells were harvested and immunoblot 
analysis was performed. Conducted by Yizhu Li. 
 
 
V.9.2 Wild-type p53 is required for protective effects of nutlin-3 
To determine whether p53 is necessary for the protective effects of nutlin-3 against 
combination therapy, we performed western blot analysis in an isogenic pair of cell lines, 
derived from HCT116, a human colon carcinoma cell line. We treated both the cell lines, 
HCT116wtp53 and HCT116p53-/-, in the similar manner as for aforementioned U2OS 
cells. HCT116 cells with wild-type p53 (HCT116wtp53) showed similar resistance to 
cytotoxic effects of combination therapy upon nutlin-3 pretreatment. In contrast, HCT116 
lacking p53 (HCT116p53−/−) did not show any effect of nutlin-3 (Figure V-XVI). 
This shows that p53 is essential for the protective effect of nutlin-3 against adverse effects 





Figure V-XVI p53 is required for protection by nutlin-3.  
Isogenic pair of HCT116 cells was pretreated with nutlin-3 for 24 h, followed by treatment with 




V.10 Long-term survival of cells treated with Wee1 inhibitor and 
gemcitabine increases upon pre-treatment with nutlin-3 
To assess the long-term survivability of cells when pretreated with nutlin-3, we treated 
U2OS cells with nutlin for 24 h followed by exposure to Wee1 inhibitor in the presence or 
absence of gemcitabine and nutlin-3. Confluency was measured and plotted 
corresponding to Day 1. After 24h, all chemicals were washed away, fresh medium was 
added and confluency of cells was measured using Celigo cytometer subsequently each 
day for 12 days. We observed that nutlin-3 increases the survival of cells treated with 
Wee1 inhibitor and gemcitabine as compared to nutlin untreated cells (Figure V-XVII). 
From these observations, we can say that normal proliferating cells with wild- type p53 
can resist the adverse effects of combination therapy by addition of nutlin while cancer 






Figure V-XVII Pretreatment with nutlin-3 increases long-term survival of the cells treated 
with Wee1 inhibitor and gemcitabine.  
U2OS cells were treated with 4µM nutlin-3 for 24 h, followed by treatment with 0.5µM Wee1i and 
5nM gemcitabine with 4µM nutlin-3. After 24 h, all drugs were removed and fresh medium was 
added. Cells were incubated for 12 days and confluency was measured each day using brightfield 
microscopy (Celigo cell cytometer). Error bars represent the SD, n=3. Conducted by Yizhu Li. 
 
 
V.11 Addition of nutlin-3 protects cells from premature mitosis 
resulting from combination therapy 
Combination of Wee1 inhibition with gemcitabine leads to premature mitosis and 
consequently to mitotic catastrophe. We investigated whether addition of nutlin could 
reduce the amount of cells entering into mitosis prematurely, which might be a 
contributing factor towards the protective effects of nutlin-3 pretreatment. Therefore, we 
performed flow cytometry with the cells treated with combination therapy in the presence 
as well as absence of nutlin and stained them with phospho-H3 antibody and propidium 
iodide. We treated the cells with combination therapy for 8h and detected the percentage 
of cells that stained positive for phospho-H3 with <4N DNA content. This percentage of 
cells corresponds to the fraction entering into mitosis prematurely. It was observed that 
the fraction of the cells entering into mitosis prematurely were significantly less upon 
nutlin-3 pretreatment after 8h of combination treatment (Figure V-XVIII). We chose 8 h 
time-point for the treatment as after 8 h, there were a high number of cells entering into 
premature mitosis. (Refer to Figure VIII-IV in appendix) 
We deduce from this study that nutlin pretreatment can reduce the number of cells 
entering premature mitosis. Thus, nutlin or its derivatives may turn out to be useful in the 








      
Figure V-XVIII Nutlin-3 pretreatment protects cells from premature mitosis caused by Wee1 
inhibitor and gemcitabine treatment.  
U2OS cells were treated with 8µM nutlin-3 for 24 h, followed by treatment with 1µM Wee1 inhibitor, 
300nM gemcitabine and 8µM nutlin-3. Cells were fixed, stained with phospho-H3 and Propidium 









VI.1 Emergence of combination therapy 
Gemcitabine has been the cornerstone of pancreatic tumor treatment. However, despite 
being the standard treatment regimen, the response rate of patients and survival has not 
been encouraging. This has been due to two major factors- first, tumor detection is 
possible only at advanced stages, and second, tumors develop resistance to gemcitabine 
(Burris 1997, M. P. Kim and Gallick 2008). Being a nucleoside analog, gemcitabine elicits 
excessive DNA damage response in tumors, eventually killing them (For mechanism, 
refer to section II.4.I). 
Inhibition of regulators of intra-S and G2 checkpoints is currently being used extensively 
to sensitize tumor cells against chemotherapeutics e.g, combination of ATR inhibition with 
cisplatin increases the sensitivity of tumors towards cisplatin (Yazlovitskaya and Persons 
2003, Perez et al. 2006, Ma et al. 2013). Abrogation of the ATR, Chk1 and Wee1 
checkpoint kinases is known to sensitize tumor cells against gemcitabine (Prevo et al. 
2012, Zabludoff et al. 2008, Rajeshkumar et al. 2011). In this project, we performed a 
comparative study in pancreatic tumor cells to identify checkpoint kinase candidate which 
is the most effective in sensitizing these tumor cells towards gemcitabine. For the 
inhibition of respective kinases, we used following inhibitors- VE-821 (ATR inhibitor), 
SB218078 (Chk1 inhibitor) and MK-1775 (Wee1 inhibitor). We evaluated their effects by 
several molecular biological methods. We identify a combination cocktail of gemcitabine 
with the Wee1 inhibitor MK-1775 to be the most potent in sensitizing pancreatic tumor 
cells against gemcitabine. 
Our findings complement previous studies which show that gemcitabine treatment along 
with concomitant checkpoint kinase inhibition increases the DNA damage response of the 
cells. We, however, do not observe any changes in gemcitabine sensitivity upon ATR 
knockdown in Panc1 cells. This could be due to a different isoform of ATR that is 
expressed in the pancreas, and might substitute for ATR loss (Mannino et al. 2001). Also, 
we found Chk1 knockdown in U2OS and BxPC3 cells does not augment DNA damage as 
compared to gemcitabine alone. The reason for such observation could be saturation of 
γH2AX signal due to gemcitabine. As a result, Chk1 inhibition does not potentiate γH2AX 
intensity.  
In addition, growth of the cells with combination treatment is hampered in long- term 




Panc1 cells. It is known that Chk1 inhibitors, specifically UCN-01 and AZD7762, can 
cause activation of the Erk1/2 and ATM pathway (Dent et al. 2011) which can contribute 
to increased survivability of cells. It has been reported that activation of Erk can have 
different effects on growth, cell cycle arrest, apoptosis and induction of drug resistance in 
different cell lineages which can depend on the presence of p53 and the expression of 
lineage specific factors (McCubrey et al. 2007). The survival effect of Chk1 inhibitor that 
we observed in the assay could be a consequence of Erk1/2 activity. Another Chk1 
inhibitor SCH 900776 has been reported to phenocopy the effects of Chk1 knockdown 
(Guzi et al. 2011). Moreover, we observed that knockdown of Chk1 alone induces 
activation of γH2AX while its inhibition does not. We propose the reason for such 
observation could be the kinase-independent function of Chk1. It is possible that inhibition 
of Chk1 still allows it to maintain fork progression through translesion DNA synthesis, a 
supplementary DNA replication process, while its knockdown cannot (Speroni et al. 
2012).  
Altogether, we find that out of three checkpoint kinase inhibitors, MK-1775 (Wee1 
inhibitor) shows higher potency in sensitizing the pancreatic tumor cells towards 
gemcitabine.  
 
VI.2 Crosstalk between Wee1 and ATR-Chk1 pathway 
Gemcitabine generates DNA damage response by activating ATR and/or ATM pathway. 
Also, Wee1 inhibition elicits DNA damage response (Domínguez-Kelly et al. 2011). We 
analyzed the overall DNA damage response generated upon Wee1 inhibition and 
observed a crosstalk between Wee1 and ATR pathway. When Wee1 inhibition is 
combined with gemcitabine, ATR-Chk1 pathway is attenuated. However, γH2AX intensity 
increases upon combination of the two drugs. Increased γH2AX might be from the activity 
of other PIKKs such as ATM or DNA- PK which get activated upon DSB formation due to 
replication fork collapse (McNeely et al. 2010). Since silencing of ATR-Chk1 pathway is 
observed independent of the status of p53 upon inhibition of Wee1 along with 
gemcitabine (Figure V-IV), we postulate that attenuation of ATR-Chk1 activity is not 
mediated through p53. Moreover, the influence of Wee1 inhibition on ATR pathway could 
be one of the reasons for its high effectiveness in combination with gemcitabine. 
Combination of Wee1 inhibitor with gemcitabine shows more PARP cleavage suggesting 
more apoptosis than gemcitabine treatment alone. Since caspase inhibition does not 
rescue Chk1 inactivation (Figure V-VII), so apoptosis could not reduce ATR activity. 




Previous reports show that inhibition of Wee1 in S-phase arrested cells leads to 
premature mitotic entry of cells resulting in mitotic catastrophe (Aarts et al. 2012). 
Interestingly, combination treatment in MCF7 cells, which resist premature mitosis when 
Wee1 is inhibited in the presence of gemcitabine, does not decrease ATR activity (Figure 
V-VIII). 
It is not known yet how Wee1 can regulate the ATR pathway in humans. Conversely, 
however, in Xenopus, Chk1 has been implicated in activation of Wee1 (J. Lee, Kumagai, 
and Dunphy 2001). Our observation of reduction in phosphorylation of Chk1 only after 12 
h (Figure V-VI) suggests that Wee1 might not be directly involved in regulation of ATR 
pathway. This led us to assess the role of Wee1 substrates, Cdks, in inactivating this DNA 
damage pathway. 
 
VI.3 Decreased activation of ATR-Chk1 pathway is mediated 
through Cyclin-dependent kinases and Polo- like kinase 1 
We show that Cdks negatively control the ATR-Chk1 pathway (Figure V-IX). Wee1 
phosphorylates Cdks at Y15 and inhibits their activity. To investigate the role of Cdks in 
modulating the ATR pathway, we inhibited Cdks with Roscovitine, which selectively 
inhibits Cdk1, Cdk2 and Cdk5 by competing for their ATP-binding domain (Bach et al. 
2005). Our results show that the regulation of ATR-Chk1 pathway is mediated through the 
activity of Cdks (Figure V-IX). Furthermore, we show that Cdk1 inhibition could rescue the 
inhibition of ATR-Chk1 pathway upon Wee1 inhibition with gemcitabine treatment (Figure 
V-X). Therefore, we can say that Cdk1 plays an important role in mediating inactivation of 
ATR pathway. This is a novel finding that has several implications in tumor therapy. 
Different Cdks have been implicated in several tumors for their diagnostic/ prognostic 
value or aberrant expression (Cicenas and Valius 2011). We postulate that use of Wee1 
inhibitor along with gemcitabine might be much more toxic in tumor cells expressing high 
levels of Cdks, therefore, it can serve as an efficient way of eliminating these cells.  
There is no evidence of direct interaction of Cdks with ATR; therefore, we tested whether 
this response is mediated through Cdk substrates. Mus81-Eme1 endonuclease complex 
has been implicated in processing of DSB and proposed to be activated by Cdk2 
(Domínguez-Kelly et al. 2011). Based on these findings, we speculated that Mus81 might 
be responsible for ATR-Chk1 inhibition once Cdk1 becomes hyperactivated due to Wee1 
depletion. However, we observed that Mus81 removal in the presence of gemcitabine 
decreased the phosphorylation of Chk1 as well as H2AX (Figure V-XI), thereby 




their study, Domínguez-Kelly and colleagues, had observed a reduction in the DNA 
damage response, generated by Wee1 removal, upon co-depletion of Mus81 
(Domínguez-Kelly et al. 2011). This possibly supports our observation of decreased 
γH2AX and phospho-Chk1 upon Mus81 removal in the presence of gemcitabine. It can be 
explained based on the fact that Wee1 inhibition leads to Cdk hyperactivation, which 
leads to deregulation of DNA replication resulting in the formation of abnormal DNA 
structures (Beck et al. 2012); these structures are resolved by Mus81-Eme1 (Domínguez-
Kelly et al. 2011). It is possible that during the processing of these structures, ssDNA is 
generated, which fortifies DNA damage response signaling (Sugawara and Haber 1992). 
Aditionally, pRb has been reported to be regulated by Cdks. Cdks phosphorylate pRb, 
thereby inactivate its binding to E2F and increase E2F-mediated transcription (Lundberg 
and Weinberg 1998). Therefore, we suspected that pRb might be involved in controlling 
the ATR-Chk1 pathway either through its substrate E2F or directly. E2F, being a 
transcription factor can possibly mediate its effect on this pathway through repression of 
ATR transcription (Ren et al. 2002, Stevens and La Thangue 2004). However, our data 
shows that of ATR-Chk1 pathway is E2F-independent as mRNA expression of ATR does 
not change upon Wee1 inhibition with gemcitabine (Figure V-XII). Moreover, pRb does 
not modulate this pathway, as even in the absence of functional pRb, inhibition of Cdk 
rescues the phosphorylation of Chk1. From here, we can say that the toxic effects of the 
combination of Wee1 inhibition with gemcitabine are independent of the status of pRb. 
Therefore, tumors having mutated or inactive pRb (Wiest et al. 2002, Xiao et al. 2002) can 
respond efficiently to this treatment thereby expanding the prospects of this combination 
therapy. 
There have been reports which link the activity of Plk1 with Cdks. In humans, Cdk1 has 
been reported to prime the Plk1 substrates by phosphorylating them. The ‘primed’ 
substrates are then recognized by Plk1, which facilitates the activation of Plk1 (K. S. Lee 
et al. 2008). In S. cerevisiae, Cdk1 maintains the stability of Plk1 by phosphorylation at 
Thr23 (Simpson-Lavy and Brandeis 2011). Furthermore, Plk1 has been implicated in 
phosphorylation of Claspin and its subsequent degradation, thereby, preventing activation 
of Chk1 in response to DNA damage signal (Mailand et al. 2006, Mamely et al. 2006, 
Peschiaroli et al. 2006). We observe that inhibition of Plk1 can rescue the attenuated 
ATR-Chk1 activity caused by Wee1 inhibition in the presence of gemcitabine (Figure 
V-XIII). This indicates the involvement of Plk1 in inactivating ATR-Chk1 pathway. We 
show that phosphorylation of Plk1 at Thr210 which is mediated by Aurora-A kinase and is 
a marker for the activation of Plk1 (Seki et al. 2008), increases upon Wee1 inhibition in 




of Plk1 in mediating inactivation of ATR-Chk1 pathway. Moreover, activation of Plk1 upon 
inhibition of Cdks is reduced. This finding supports the previous literature that Cdks assist 
in Plk1 activation. We also find decreased Thr210 phosphorylation on Plk1 upon Plk1 
inhibition (Figure V-XIII). The Plk1 inhibitor, GSK461364 is an ATP-competitive inhibitor 
of Plk1 (Olmos et al. 2011), however, how this inhibitor affects Aurora-A kinase mediated 
activation of Plk1 remains to be understood.  We also show that indeed Plk1 mediates 
inactivation of Chk1 through Claspin degradation (Figure V-XIV).  
Inhibition of Wee1 with gemcitabine increases the Plk1 activation (Figure V-XIII), and the 
activated Plk1 drives the cells into mitosis (Seki et al. 2008) which can be a reason for 
mitotic catastrophe. It is because the cells undergo replicative stress with gemcitabine but 
upon inhibition of Wee1, Plk1 activation causes the cells with unreplicated DNA to enter 
into mitosis resulting in cell death. Now, we show Plk1 also mediates inactivation of ATR-
Chk1 pathway. Thus, altogether, unregulated Plk1 activity in already stressed cells is 
lethal to the cells.  
Plk1 activation requires Bora protein (Seki et al. 2008) and the protein levels of Bora are 
found to be high in some cases of pancreatic cancer 
(http://www.proteinatlas.org/ENSG00000136122/cancer dated140815). From here, we 
predict that the combination of Wee1 inhibitor and gemcitabine in these cells can prove to 
be quite toxic due to high activation of Plk1 and thus, resulting inactivation of ATR-Chk1 
pathway. Furthermore, it may be worth testing if removal of Bora from the cells produces 
the same effects as inhibition of Plk1.  
From the results obtained, we propose the following model- 
 
Figure VI-I Wee1 inhibition hampers ATR-Chk1 activity.  
Inhibition of Wee1 hyperactivates Cdk1 which, in turn, promotes Plk1 activation. Activated Plk1 
leads to Claspin degradation; consequently ATR-Chk1 activity is attenuated. Plk1 might regulate 





VI.4 Attenuating the side-effects of combination treatment by 
nutlin-3 pretreatment 
The nucleoside analogues and other drugs that induce replicative stress lead to undesired 
effects by causing the destruction of rapidly dividing normal cells. These include 
hematopoetic cells (mostly in the bone marrow) as well as the epithelia of the gut, and 
hair follicles (Galmarini, Mackey, and Dumontet 2002). Indeed, the dose-limiting toxicity of 
gemcitabine causes myelosuppression, as for many other DNA-damaging 
chemotherapeutics (Fossella et al. 1997). This raises the need to provide specific 
protection to normal cells. 
To protect normal dividing cells from the toxic effects of chemotherapy, the checkpoint 
machinery can be exploited. In normal cells, p53 is present in wild-type form while in most 
of the cancer cells, it is mutated or absent (Nigro et al. 1989). Wild-type p53 is activated 
by nutlin-3; however, the drug has no effect on mutant p53 (Coll-Mulet et al. 2006). This 
differential activity of nutlin-3 has been utilized to protect the healthy cells from cytotoxicity 
caused by chemotherapeutic drugs. In the work done by Kranz and colleagues, nutlin-3 
protects the wild-type p53 containing cells against gemcitabine. Gemcitabine induces 
DNA damage and apoptosis in cancer cells irrespective of their p53 status, nevertheless 
when these cells are pretreated with non-toxic amounts of nutlin-3, cells with wild-type 
p53 show reduced DNA damage response and cell death (Kranz and Dobbelstein 2006). 
Activation of wild-type p53 causes transient cell cycle arrest in G1 or G2, mostly through 
the induction of the CDKN1A gene, encoding the cyclin dependent kinase inhibitor p21, 
with subsequent hypophosphorylation of the retinoblastoma family of proteins and 
repression of E2F target gene (Polager and Ginsberg 2009). If this happens, the cells will 
be protected against therapeutic regimens that rely on the enhancement of replicative 
stress, e. g. nucleoside analogues. We find that nutlin-3 pretreatment could rescue the 
wild-type p53 containing cells from lethal effects of the combination of Wee1 inhibition and 
gemcitabine. Apart from attenuating the DNA damage response and apoptosis, we 
observe that nutlin-3 pretreatment could also reduce the protein levels of phosho-H3, a 
mitotic marker (Figure V-XV). This indicates that nutlin-3 could protect the cells from 
entering into mitosis, which is induced by Wee1 inhibition. As Wee1 inhibition leads to 
premature entry of cells into mitosis, we measured the number of cells entering into 
mitosis prematurely using mitotic marker phospho-H3 and cell cycle analysis. Our results 
show that premature mitosis decrease significantly in cells pretreated with nutlin-3 (Figure 
V-XVIII) which can be due to G1 or G2 arrest caused by induction of p21. As expected, 




protects Mdm2 from degradation as well as causes increase in Mdm2 transcription 
(Leeuwen et al. 2011). However, for unknown reasons, combining Wee1 inhibitor (either 
alone or with gemcitabine) with nutlin-3 did not stabilize Mdm2. We also show that wild-
type p53 is required for the protective function of nutlin-3 as the cells without p53 remain 
unaffected by the addition of nutlin-3 (Figure V-XVI).  
This study reflects the beneficial use of Mdm2 antagonists in clinics. When treating the 
patients with combination therapy, addition of these antagonists at sub-lethal dose could 
help reduce side-effects of the combination treatment.  
 
VI.5 Conclusions 
Our data shows that Wee1 inhibition decreases activity of Chk1; however, there are 
studies which find cooperative effects when using inhibitors of Chk1 and Wee1 
simultaneously for cancer treatment (Davies et al. 2011, Guertin et al. 2012). Here, we 
propose that this cooperativity between Chk1 and Wee1 inhibitor might explained by the 
timing of the Chk1 inactivation. As, we observe decrease in Chk1 activity upon Wee1 
inhibition only after a couple of hours. For the increased sensitization of cells, inhibition of 
Chk1 might be required immediately after the addition of nucleoside analogues. 
Moreover, the cell type and the choice of concomitant chemotherapies may also affect the 
cooperativity between inhibitors of Wee1 and Chk1. In any case, we show here that at 
least in the presence of gemcitabine, Chk1 and ATR can be attenuated by Wee1 inhibitor 
alone. 
Our results strongly suggest that Wee1 inhibition kills cancer cells not only by premature 
entry of cells to mitosis and resulting mitotic catastrophe (Aarts et al. 2012) but also by 
augmenting replication stress through impairment of ATR-Chk1 signaling. This unique 
combination of cytotoxic mechanisms, triggered through a single target, provides an 
explanation for the remarkable cytotoxic efficacy of Wee1 inhibitors. Wee1 inhibitors 
represent promising anti-cancer drug candidates (Rajeshkumar et al. 2011, Do et al. 
2013) and are currently being tested in clinical trials of phases I and II (NCI Clinical 
Trials). 
Chemotherapies that enhance replicative stress above the endogenous level also affect 
non-malignant cells, presumably resulting in unwanted toxicities. Therefore, to protect 
normal cells from replicative stress without compromising the cytotoxic effects on tumor 
cells, it is necessary to exploit characteristic differences between malignant and normal 




cells against the combination of Wee1 inhibitor and gemcitabine. We propose that this 
approach can possibly be transferred to the clinics to evaluate the protective effects of 
Mdm2 antagonists against replicative stress. 
 
VI.6 Future perspectives 
Recent studies have shown the regulation of Wee1 by miRNAs. In some tumors, levels of 
miRNAs suppressing Wee1 expression have found to be up-regulated (Butz et al. 2010, 
Bhattacharya et al. 2013), treatment of such tumors with nucleoside analogs might be 
beneficial.  
To further study the mechanism leading to down-regulation of ATR activity, the protein 
called CtIP seems to be a good candidate. Donnianni and colleagues have shown in 
budding yeast that Sae2, which is a functional ortholog of human CtIP, is regulated by 
Plk1 (cdc5 in yeast) and is involved in silencing of DNA damage signaling (Donnianni et 
al. 2010). In S. cerevisiae, Sae2 negatively regulates checkpoint signaling by modifying 
the association of MRX at damaged DNA sites. Depletion of Sae2 in the cells prevents 
the Mec1 (ATR)- and Tel1 (ATM)–dependent signaling to turn off and interrupts with the 
disassembly of Mre11 foci at DNA breaks (Clerici et al. 2006). In contrast, in one of the 
studies in humans, CtIP has been reported to resect DSBs and thus, recruit RPA and 
ATR to the DSB sites, subsequently leading to ATR activation (Sartori et al. 2007). In a 
recent study, CtIP is shown to be required for sustaining the ATR-Chk1 pathway while it is 
not necessarily required for initiating its activation (Kousholt et al. 2012). However, both of 
the studies in humans present CtIP as a positive regulator of the checkpoint signaling 
pathway. Study can be performed to determine the role of CtIP in DNA damage signaling 
upon combination treatment and its regulation by Plk1. It is possible that phosphorylation 
of CtIP by Plk1 is responsible for different responses of CtIP upon DNA damage. It might 
be possible that both the effects are mediated by CtIP in a time-dependent fashion. 
Initially, CtIP is required for maintaining ATR-Chk1 activation but once the resection is 
completed, it mediates to turn off this pathway. Moreover, CtIP has been found to be 
phosphorylated by Cdks and this phosphorylation along with another phosphorylation 
mediates binding of Pin1 protein to CtIP. Pin1 isomerization with CtIP facilitates its 
degradation (Sartori and Steger 2013). Also, Plk1 has been found to stabilize Pin1 protein 
(Eckerdt et al. 2005). Therefore, we speculated that upon inhibition of Wee1, hyperactive 
Cdks phosphorylate CtIP and activated Plk1 stabilize Pin1, which ultimately facilitates 




A previous study has shown that replicative stress caused by Wee1 inhibition due to 
deregulated Cdk activity can be suppressed by supplementing the cells with nucleosides. 
Inhibition of Wee1 causes increased Cdk activity which leads to augmented initiation of 
replication, resulting in scarcity of nucleotide and reduced replication fork speed, followed 
by Mus81-mediated DNA double strand breakage. When nucleosides are added, they 
stabilize the fork speed and reduce DNA DSB formation  (Beck et al. 2012). Based on 
these observations, it can be tested if the addition of nucleosides has any effect on the 
ATR-Chk1 activity upon addition of Wee1 inhibitor in gemcitabine-treated cells. 
Since a long time, combinatorial approaches have been applied in classical 
chemotherapeutical regimens, including nucleoside analogues, platinum compounds, 
and/or topoisomerase inhibitors. Combinations of these drugs are usually more effective 
than single drugs and have been tested in multiple clinical trials. However, the knowledge 
on how these drugs affect each other’s efficacy at molecular level is very limited. 
Therefore, we consider that investigating in this area may promote the development of 
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Efficiency of inhibitors 
                         
Figure VIII-I Checkpoint kinase inhibitors efficiently inhibit their target kinases. 
Panc1 cells were treated with 5µM Chk1i, 1µM Wee1i and 10µM ATRi in the presence of 300nM 
gemcitabine for 24 h. Blots were stained for the phosphorylation of substrates of each kinase- 
Cdk1 for Wee1, Chk1 and Chk1 for ATR. HSC 70 was stained as loading control. Chk1 controls 





Figure VIII-II Wee1 #1 siRNA was quite efficient in removing the Wee1 protein. 
Panc1 cells were transfected with the negative control no. 1 (Control), Wee1 (Wee1 #1, #2) 
siRNAs and incubated for 48 h. Afterwards, cells were treated with gemcitabine for 24 h and then 







Figure VIII-III Two different siRNAs against Chk1 are efficient in knockdown of Chk1 protein. 
Panc1 cells were transfected with the negative control no. 2 (Control), Chk1 (Chk1 #1, #2) siRNAs 
and incubated for 48 h. Afterwards, cells were treated with gemcitabine for 24 h and then 




Double thymidine block 
We observed that inhibition of Wee1 in the absence or presence of gemcitabine increases 
the premature entry of cells into mitosis. Treatment with Wee1 inhibitor and gemcitabine 
causes a significant increase in the number of cells with unreplicated DNA in mitosis as 
early as after 8 h of treatment. 




















Figure VIII-IV Cells with Wee1 inhibition in the absence or presence of gemcitabine show 
entry into premature mitosis. 
U2OS cells were synchronized using double thymidine block. Afterwards, treatment with 
gemcitabine or Wee1 inhibitor or a combination of both drugs was done and cells were harvested 
at different time points. Y-axis represents PI intensity which corresponds to the DNA content of the 
cells. X-axis represents MPM-2 intensity which corresponds to cells present in mitosis. Green dots 
represent the cells stained positive for MPM-2 intensity and the dots present near 50 units of PI 
intensity correspond to the cells entering mitosis prematurely. 
 
 
 
 
 
 
 
 
 
 
